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Epigenetics refers to the study of heritable changes in gene expression that do not involve 
changes in the underlying DNA sequence. Typical investigated epigenetic marks include DNA 
methylation, modifications to histone proteins, and more recently DNA 5-hydroxymethylation 
(5hmC). Epigenetic profiles in carcinogenesis have been a topic of increasing interest, with 
several studies showing that epigenetic silencing of tumor suppressor genes and de-repression of 
heterochromatic intergenic regions via DNA methylation dysregulation play essential roles. 
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide, 
and accumulated scientific evidence suggests that epigenetic alterations, especially DNA 
methylation, are frequently involved in oral carcinogenesis, tumor progression, and resistance to 
therapy. In addition to cancer, other diseases and exposures can also modify the epigenome.  For 
instance, environmental contaminants and toxicants such as the chemical DEHP, have been 
shown to alter epigenetic regulatory features such as DNA methylation and hydroxymethylation. 
Infection with a high-risk strain of human papillomavirus (HPV) has been shown to be a 
risk factor for HNSCC development. Characteristics of HPV(+) HNSCC include higher risk of 
distant metastasis, poor differentiation, and more favorable prognosis, while HPV(-) HNSCC 
tends to progress locally and exhibit a higher level of differentiation and greater resistance to 
treatment. Previous studies have identified DNA methylation differences between these two 
classes of HNSCC, but we are the first to characterize 5hmC in HNSCC by HPV status (18 
HPV(+); 18 HPV(-)). In Chapter 2, we showed significant hyper-hydroxymethylation in HPV(-) 
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tumors, characterized the heterogeneity in 5hmC in promoters and enhancers relative to tumor 
subtypes and clinical variables, and detected important cancer genes with differential 5hmC by 
HPV status and between subtypes.  
In terms of clinical treatment in HNSCC, in Chapter 3, we tested the transcriptomic and 
epigenomic effects of a multi-component drug regimen called IRX-2 in a phase II clinical trial; 
IRX-2 is a human cell-derived biologic with multiple active cytokine components. The treatment 
regimen consists of 10 days of regional perilymphatic IRX-2 cytokine injections and daily oral 
indomethacin, zinc and omeprazole (Regimen 1) compared to the identical regimen without 
IRX-2 cytokines (Regimen 2). By comparing the IRX-2 versus control arms after 21 days of 
trial, we were able to characterize the significant change of more than 100 genes using 
NanoString immune gene expression data and explore the correlation between response (clinical 
and immunological) and immune signatures. The exploration of DNA methylation showed a 
slight overall increase in methylation after treatment in both regimens, especially for immune 
responders in the IRX-2 study arm. Although a small number of genes were identified that 
distinguished the IRX-2 from the control arm, most beneficial changes were common to both, 
suggesting that much of the benefit of the full IRX-2 treatment regimen is due to components 
other than the cytokine cocktail.  
In Chapter 4, we focused on the epigenetic effect of early-life di-2-ethylhexyl phthalate 
(DEHP) exposure. DEHP is the most common member of the class of phthalates, and DEHP 
exposure during pregnancy has been shown to disrupt placental growth and development in 
mice, resulting in higher rates of low birthweight, premature birth, and fetal loss. We studied the 
effect of perinatal DEHP exposure on the DNA methylation profile in liver (a primary target 
tissue of DEHP) and blood (a common surrogate tissue) of both juvenile and adult mice. Despite 
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exposure ceasing at 3 weeks of age (PND21), we identified thousands of sex-specific differential 
DNA methylation events in 5-month-old mice, more than identified at PND21, both in blood and 
liver. However, only a small number of these differentially methylated cytosines overlapped 
between the time points, or between tissues (i.e. liver and blood), indicating changes by age and 
that blood may not be an appropriate surrogate tissue to estimate the effects of DEHP exposure 
on liver. 
 In summary, we facilitated the interpretation of epigenetic effects by exploring the 5hmC 
profile in head and neck cancer, characterizing the immune response gene expression and DNA 
methylation in oral cavity cancer immunotherapy, and capturing the effects of DEHP exposure 
on DNA methylation in mouse models. 
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 Chapter 1 Introduction 
 
1.1 Introduction to epigenetics  
Epigenetics refers to the study of heritable chemical or physical changes that do not involve 
changes in the underlying DNA sequence. Typical investigated epigenetic marks include DNA 
methylation, modifications to histone proteins, and more recently DNA 5-hydroxymethylation 
(5hmC) (1). Epigenetic modifications have been shown to be correlated with many human 
diseases, including different cancers, autoimmune disorders, neurological disorders, aging and 
response to environmental exposures (2–5). Histone modification is a covalent post-translational 
modification to histone proteins, and many types of histone modification events include 
methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation (6). These 
modifications regulate the chromatin structure either directly or by recruiting remodeling 
enzymes, and they can both positively and negatively regulate gene expression by changing the 
way in which histones bind to DNA (7). 
DNA methylation indicates the process of adding a methyl group to bases in the DNA 
sequence, and the most commonly studied modification is the methylation of the C5 position on 
cytosine bases, which is called 5-methylcytosine (5mC) (Figure 1.1, modified from (8)). TET 
(ten-eleven translocation) proteins can oxidize 5mC to 5-hydroxymethylcytosine (5hmC) and 
other oxidative derivatives, and hydroxymethylation refers to the addition of hydroxymethyl 
group instead of methyl group. The conversion from 5mC to 5hmC results in a loss of 
transcriptional repression in promoters or enhancers, and is a common mechanism to activate 
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genes in differentiation and development (9). Genomic 5hmC is a relatively stable component of 
DNA, or can act as an intermediate in DNA demethylation by replication-dependent or 
replication-independent pathways, and it plays an essential role in the regulation of gene 
expression (10,11).  
 
Figure 1.1 Chemical structures of 5-methylcytosine (5mC) and 5-
hydroxymethylcytosine (5hmC) and their potential associations with gene regulation 
 
1.2 Methods to capture epigenetics 
The rapid growth and lower cost of high-throughput sequencing methods and other molecular 
technologies have helped capture epigenetic profiles more accurately. Histone modifications can 
be detected using a variety of techniques including mass spectrometry and genomics approaches 
such as chromatin immunoprecipitation (ChIP), which can identify the location of a protein or 
modification of interest within the genome and measure its relative abundance at each location. 
There are two main methods to measure DNA methylation, which are affinity enrichment based 
and bisulfite-based methods (12). At a lower cost, the affinity enrichment strategies include 
methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain protein (MBD)-
based methods, which generally have lower resolution and a higher input requirement. The 
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bisulfite conversion methods include whole genome bisulfite sequencing (WGBS), which was 
considered the gold standard for several years, reduced representation bisulfite sequencing 
(RRBS), and Infinium (MethylationEPIC BeadChip, which interrogates over 850,000 
methylation sites quantitatively), and though more labor and computationally intensive, they 
have low input requirement and single-nucleotide resolution (13). However, it is important to 
note that these standard bisulfite-based techniques cannot distinguish 5mC from other 5-carbon 
cytosine modifications, including 5hmC, whereas the affinity-based approaches are specific to 
one mark. 
5hmC is the most prevalent intermediate on the oxidative DNA demethylation pathway, and 
multiple methods have been developed to capture the genomic 5hmC profile. Examples of 
affinity enrichment methods include hydroxymethyl-DNA immunoprecipitation sequencing 
(hMeDIP-seq), where a monoclonal 5-hmC antibody was used (14). Bisulfite conversion 
methods can be adjusted to characterize 5hmC, and the most common methods include OxBS-
seq (Oxidative bisulfite sequencing, with an additional oxidative step to bisulfite to discriminate 
between 5mC and 5hmC) and TAB-seq (use of TET to distinguish 5mC and 5hmC) (15,16). 
Recently, a few newer and more efficient approaches to detect 5hmC at base resolution were 
introduced, such as Jump-seq (5hmC was labeled by the 6-N3-glucose moiety and connected to a 
hairpin DNA oligonucleotide) and TAPS-seq (TET-assisted pyridine borane sequencing; a 
bisulfite-free method to both 5mC and 5hmC detection) (17,18).  
 
1.3 Epigenetics in head and neck cancer 
In human cancers, alteration of DNA methylation patterns is frequently observed. On one 
hand, hyper-methylation patterns in the promoters of tumor suppressor genes could inhibit their 
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normal expression, resulting in changes in crucial biological processes, such as proliferation and 
cell cycle checkpoints, apoptosis, cell cycle, DNA repair, tumor invasion, and metastasis (19,20). 
On the other hand, global hypomethylation and hypomethylation at retrotransposon elements, 
centromeres and oncogenes can also induce genomic instability and contribute to cell 
transformation (21). In particular, lower methylation level in long interspersed elements (LINEs) 
or short interspersed elements (SINEs) is highly associated with carcinogenesis through genome 
destabilization (22). Global reduction in 5hmC has been observed in many cancer types studied 
to date (23–25), which are frequently associated with mutations in TET2 (26,27). More recent 
studies showed that the inhibition of TET activity by the onco-metabolite 2-hydroxyglutarate 
which accumulates through mutations of isocitrate dehydrogenases (IDH1/2) are also involved in 
the dynamic regulation of 5hmC levels (28,29). 
Head and neck squamous cell carcinoma (HNSCC) is heterogeneous disease that involve 
multiple sites and cellular origins within the upper aerodigestive tract, which includes tumors in 
the oral cavity, larynx, oropharynx, and hypopharynx, and is the sixth most prevalent cancer 
worldwide(30–32). Globally, HNSCC affects approximately 680,000 patients and causes 
330,000 deaths every year, with a five-year survival rate ranging from 37% to 62% (33,34),. 
While tobacco and alcohol consumption are long-recognized risk factors, high-risk strains of 
human papillomavirus (HPV), in particular HPV-16, account for an increasing number of cases 
(35). Epigenetic differences between normal and HNSCC tumor tissue are extensive, and there is 
increasing evidence showing that epigenetic modifications could be a potential cause of HNSCC, 
as shown by multiple genome-wide DNA methylation studies (32,36–39). Both 
hypermethylation and hypomethylation of promoter regions in HNSCC has been reported in 
many studies, and many genes are frequently analyzed such as p16, PTEN, DAPK, MGMT, 
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ECAD and RASSF1 (40). Another study re-evaluated the HNSCC DNA methylation markers, 
and hypermethylation of FAM135B and ZNF610 and hypomethylation of HOXA9 and DCC 
were validated from several HNSCC studies and 450K BeadChip data from The Cancer Genome 
Atlas (TCGA), and hypermethylation of FAM135B was significantly correlated with overall 
survival (41–43). The methylation alteration retrotransposon elements was also confirmed in 
HNSCC, where Arayataweegool et al. discovered hypomethylation of LINE-1 elements in 
coculture with cancer cells due to factors secreted by HNSCCs (44). 
Compared with the relatively well studied DNA methylation events, only a few studies focus 
on hydroxymethylation in HNSCC. With the use of Immunohistochemistry methods, an early 
study by Jawert et al. discovered the loss of 5hmC and TET2 in oral squamous carcinoma, which 
is consistent with the observations in other cancer types (45). A more recent study using enzyme-
linked immunosorbent assay and quantitative real-time PCR also low levels of 5hmC in HNSCC, 
and 5-hmC levels were significantly correlated with tumor stage and better disease-free survival 
(46). 
 
1.4 HPV infection and head and neck cancer 
During the last few decades, human papilloma virus (HPV) has emerged as a novel risk 
factor of HNSCC, especially for oropharyngeal squamous cell carcinoma (OPSCC) (47). HPV is 
a family of double-stranded DNA viruses of 8000 base pairs, and it can induce carcinogenic 
transformation of the infected mucosal epithelium by escaping cell-cycle checkpoints through 
degradation of p53 and Rb proteins, which is mediated by the accessory proteins E6 and E7, 
respectively (48,49). E6/E7 expression is frequently associated with integration of the viral 
genome into DNA regions of genomic instability, which is observed in the majority of invasive 
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cervical cancer and HPV(+) HNSCC (50). There are multiple methods to detect the presence of 
HPV, including E6/E7 HPV mRNA RT-PCR, HPV DNA in situ hybridization, p16in situ 
hybridization and measurement of HPV mRNA expression using high-throughput sequencing 
techniques (51,52). 
 HPV(+) HNSCC patients generally show better therapeutic response, improved prognosis 
and higher overall survival than their HPV(-) counterparts, with 5-year survival rates of 75–80% 
(53–55). At the molecular level, the gene CDKN2A (p16) is a marker for HPV etiology, due to 
its high expression level in HPV(+) tumors and common loss in HPV(-) tumors(56). HPV(+) 
HNSCC also have frequent activating mutations of genes involved in phosphoinositide 3-kinase 
(PI3K) pathway, affecting translation and transcription of multiple targets that are involved in 
various cellular properties such as proliferation, survival and motility (57,58). With tobacco 
consumption as the primary risk factor for development, HPV(-) HNSCC is often accompanied 
by p53 mutation, CDKN2A deletion or PIK3CA amplification (59). A few studies have 
examined molecular inter-tumor heterogeneity and identified subtypes of HNSCC (60–62), with 
the characteristic differences in global gene expression profiles between HPV(+) and HPV(-) 
tumors and among subtypes now established. Results point to differences by HPV status and 
tumor subtypes in several carcinogenic pathways, including basal epithelial-to-keratinocyte 
proliferation, immune response, cell adhesion and induction of DNA damage, that often correlate 
with clinical outcome (60,62). 
During the last five years, multiple studies have discovered new evidence identifying 
different characteristics that define the main HPV(+) HNSCC subtypes. Based on gene 
expression profiling of a combination of 18 HPV+ HNSCC from University of Michigan 
Hospital and 66 TCGA HPV(+) HNSCC samples, Zhang et al. revealed two major HPV(+) 
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subtypes, named IMU and KRT. The IMU subtype was identified by a higher level of immune 
response and more mesenchymal differentiation, whereas the KRT subtype is identified by 
stronger keratinization and viral integration events (60). The study also linked the IMU subtype 
with stronger epithelial-to-mesenchymal transition (EMT) signatures and higher BCL2 gene 
expression, which could be contributing factors to IMU subtype’s better prognosis.  
The investigation of HPV integration status of the same cohort showed that the KRT subtype 
had more samples with HPV genic integration than the IMU subtype. The KRT group also 
showed lower expression of viral genes E2, E4, and E5. By analyzing SNP-array data from 
tumors and blood from the same cohort, the authors were able to identify more amplifications in 
KRT tumors than IMU, especially at chromosomal arms, and being compared with the results 
from gene expression suggested that the gain and loss of copy numbers can partially drive the 
expression differences between the two subgroups. In term of the differences in gene mutation 
frequencies between the two HPV(+) subtypes, the analysis on non-synonymous mutation from 
RNA-seq data and TCGA gene-level somatic mutation data displayed only one mutation with a 
difference of more than 20% between two groups, which occurred on oncogene PIK3CA in 37% 
of the KRT samples and only 16% of the IMU samples. By retrieving gene expression from 11 
HNSCC studies, Locati et al. characterized three distinct HPV(+) subtypes, defined as Cl1 
(immune-related), Cl2 (highly keratinized, epithelial mesenchymal transition-related), and Cl3 
(highly keratinized, proliferation-related) (62). The Cl1 subtype was in agreement with the IMU 
subtype, while the KRT subtype was further stratified into Cl2 and Cl3 by their biological and 
prognostic characteristics. 
A more recent study looked at the genetic variants profile of the same cohort of patients, with 
the use of a combination of mRNA-seq-based variant analysis and targeted gene sequencing on 
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matched tumor and blood samples (63). Although this study did not discuss any HPV(+) subtype 
specific mutation, it did identify a germline variant in a cancer related Fanconi Anemia (FA) 
pathway gene which was harbored by more than a third of patients.  
 
1.5 Immunotherapy in head and neck cancer 
The definition of cancer immunotherapy, or immuno-oncology, is a type of cancer treatment 
that uses components of the immune system to prevent, control, or eliminate cancer. There are 
many forms of immunotherapy, including checkpoint inhibitors, targeted antibodies, cancer 
vaccines, adoptive cell transfer, tumor-infecting viruses, and immune system modulators (64). 
Depending on the nature of treatment, cancer immunotherapy comes in forms of intravenous 
(IV), oral, topical, or intravesical. Checkpoint inhibitors are monoclonal antibodies that block the 
certain immune cells that need to be activated (65), and they work by blocking checkpoint 
proteins from binding with their partner proteins. Most widely used drugs target CTLA-4 and 
PD-1 (or partner protein PD-L1). As originally published by the National Cancer Institute, 
checkpoint inhibitors have been approved to treat a variety of cancer types, such as breast cancer, 
cervical cancer, colon cancer, Hodgkin lymphoma, liver cancer, lung cancer, and head and neck 
cancer, with response rate increasing from 6% to 13% during the last few years (66). Cytokines 
are proteins produced by white blood cells, and they are the most common form of immune 
modulators. The types of cytokines frequently used to treat cancer include interferons (INFs; 
inhibit B cell activation, enhance T cell activity, and increase the cellular-destruction capability 
of natural killer cells) and interleukins (ILs; regulate activated T cell proliferation and promote 
activation-induced cell death) (67). Other types of immune modulators include agonists, which 
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can activate pathways that promote adaptive immune responses, and adjuvants, which can 
activate pathways involved in the innate immune system. 
Currently there are four approved monoclonal antibodies targeting PD-1 and PD-L1.The 
drugs nivolumab (opdivo) and pembrolizumab (keytruda) are anti-PD-1 antibodies, while 
avelumab (bavencio) and atezolizumab (tecentriq) are anti-PD-L1 antibodies (68,69). The first 
trial evaluating PD1/PDL1 inhibitor in HNSCC was published in 2016, where pembrolizumab 
was used for treatment of recurrent or metastatic HNSCC (70,71). The overall response rate was 
18% during the Phase I trial regardless of HPV status, and the response rate stayed stable at 16% 
during the Phase II trial on HNSCC patients pre-treated with platinum and cetuximab (72). 
During the Phase III trial, the patients were allocated at a 2:1 ratio to receive either nivolumab or 
standard single-drug systemic therapy, and patients treated with nivolumab appeared to have 
longer overall survival, though lower than the pre-specified cutoff for survival improvement 
(73,74). In 2019, another Phase III clinical study using pembrolizumab in the treatment of 
relapsed or metastatic HNSCC reported superior treatment results in the pembrolizumab group 
(75). Based on the positive outcome, both nivolumab and pembrolizumab have been approved by 
the FDA for patients with relapsed or metastatic HNSCC who are cisplatin-resistant (76).  
A number of trials have evaluated PD-L1 expression by IHC on HNSCC tumor cells alone or 
in combination with PD-L1 expression on tumor-infiltrating immune and stromal cells, so as to 
understand the association between certain gene expression and immunotherapy outcome. For 
instance, the aforementioned clinical trial showed that tumor PD-L1 expression generally 
correlates with improved efficacy with anti-PD-1/PD-L1 checkpoint inhibitors in HNSCC, with 
increased predictive value when including PD-L1 expression on tumor infiltrating immune cells 
(77). Apart from immune-related gene expression, epigenetics could also play an important role 
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in HNSCC immunotherapy. For instance, a Phase 2b clinical trial (NCT03019003) was 
conducted to test whether low dose of a demethylating agent (5’aza) is able to prime patient’s 
immune response for immune checkpoint inhibitor therapy. In a few recent immune-related 
HNSCC studies, the characterization of DNA methylation profiles predicted a combination of 
hyper- and hypo-methylation markers in response to immune checkpoint inhibitors, and these 
methylation signatures could act as surrogate biomarkers to predict the objective response rate of 
PD-1/PD-L1 inhibition (78–81). 
Immunomodulatory drugs are also known as biological response modifiers priming immune 
response in patients, and currently there are four drugs, namely, thalidomide (Thalomid), 
lenalidomide (Revlimid), pomalidomide (Pomalyst) and imiquimod (Aldara, Zyclara) in cancer 
treatment. Thalidomide, lenaliodomide, and pomalidomide are used to treat multiple myeloma, 
and they can boost the IL-2 release in cells, as well as stop tumors from forming new blood 
vessels (82,83). Imiquimod is a drug that is a cream applied to skin, and it can stimulate local 
immune response against skin cancer cells. Another form of immune modulation treatment is the 
use of Bacillus Calmette-Guérin (BCG), a weakened form of the bacteria that causes 
tuberculosis. BCG is a liquid put into the bladder through a catheter to treat early-stage bladder 
cancer, and as one of the earliest immunotherapies, it can also be used melanoma skin cancers 
(84). However, no immune modulation drugs have been approved in HNSCC to date. 
 
1.6 Epigenetics in DEHP exposure 
Environmental exposures compose of many forms, such as chemicals, metals, or particles, 
and can affect animal and human health negatively. For instance, various forms of exposures can 
alter the normal function of the endocrine system or harm the nervous, hematopoietic, 
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respiratory, or digestive systems by releasing toxins (85). Di(2-ethylhexyl) phthalate (DEHP) is a 
plasticizer (86) often found in polyvinyl chloride products, including medical equipment, car 
upholstery, food and beverage containers, and building materials (87). DEHP does not covalently 
bond to polymer chains in these products and is therefore likely to spread into the environment 
after repeated usage (88). Humans are exposed to DEHP through ingestion, inhalation and 
dermal exposure, and the exposure to DEHP is considered a universal and ubiquitous event 
(89,90). Due to the large quantity and wide variety of products containing DEHP that people 
interact with frequently, the estimated range of human exposure to DEHP is 3-30 μg/kg/day (91).  
DEHP is a type of endocrine disruptor and a probable carcinogen, and has been detected in 
tissues such as blood, amniotic fluid, umbilical cord blood, and breast milk in humans (92–95), 
indicating that exposure starts as early as the fetal developmental stage, impacting generations 
that were not directly exposed to the chemical (96). The effect of DEHP can last across multiple 
generations during critical developmental window (97). The estimated human oral absorption 
varies from 25% to 50% depending on the dosage (98,99), while absorption in rodents can be as 
high as 58% of the oral dose, but 50% is assumed on average (100). The biological action of 
DEHP is very similar to a group of chemicals called peroxisome proliferators (PPs), and liver is 
a primary target organ for the effects of DEHP and other PPs (101). Prenatal DEHP exposure in 
rodents results in elevated fatty acid metabolism, as well as peroxisome proliferation and the 
accumulation of lipofuscin granules which are implicated in hepatocarcinogenesis (102,103). 
There are multiple modes of action of DEHP in hepatocytes, with the most well-known ones 
being activation of peroxisome proliferator-activated receptors (PPARs), induction of cell 
proliferation, suppression of apoptosis, oxidative DNA damage, and inhibition of gap junctional 
intercellular communication (101,104). PPARs can regulate histone deacetylation and DNA 
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methylation, and modulate a series of mechanistic pathways leading to increase in adipocyte 
formation and fat storage (105,106). Once absorbed, DEHP and its metabolites are distributed 
throughout the body via the blood promoting its endocrine disrupting properties.  
Epigenetics, such as non-coding miRNA and DNA methylation, define and control cell and 
tissue development by regulating gene expression (107), and may mediate the effects of 
exposures. For example, Scarano et al. proposed that the long-term reproductive defects 
associated with phthalate exposure is exerted through non-coding miRNAs (108). DNA 
methylation, especially methylation patterns of imprinted genes is crucial for embryonic 
development (109). Previous animal and human studies have reported that perinatal exposure to 
DEHP is associated with altered DNA methylation (110–112), with multiple studies identifying 
DEHP‐induced DNA hyper‐methylation (113,114). A recent study in human cord blood showed 
significant DNA methylation changes in genes involved in androgen and estrogen responses, and 
spermatogenesis following prenatal DEHP exposure (115). Other studies of ovaries and oocytes 
showed prenatal DEHP exposure disrupted the expression of cell cycle regulators and changed 
the DNA methylation pattern of imprinted genes in germ cells (109,116). As the primary organ 
for filtering toxicants within the body, liver has also been identified as a primary target organ of 
DEHP. A recent study showed that DEHP exposed mice livers exhibited significant changes in 
global DNA methylation levels in all three subsequent generations, and the expression levels of 
DNA methyltransferase 1 (Dnmt1), which can establish and maintain DNA methylation patterns, 
were significantly changed in both the F1 and F2 generations (117,118). However, DNA 
methylation was only quantified using Nanodrop in this study, and the effect of prenatal DEHP 




1.7 Dissertation overview 
The epigenetic effects in both head and neck cancer and DEHP exposure have been 
described, but several questions remain to be answered in order to further understand the 
epigenetic mechanisms in the respective conditions. Compared with the abundance of literature 
in genetics, the field of epigenetics is not as well studied in head and neck cancer, especially in 
terms of the epigenetic differences within different HNSCC subtypes. With the increasing 
importance of HPV infection in HNSCC, it is essential to not only capture the epigenetic profiles 
of HPV(+) and HPV(-) tumors separately, but also investigate the epigenetic marks of subtypes 
within each tumor group. Even though immunotherapy has gained increasing usage in multiple 
cancer types, only a limited number of checkpoint inhibitor drugs are available for head and neck 
cancer. There is an urgent need to explore more types of immunotherapy in HNSCC, such as 
immune modulation drugs, as well as capture the immune profile of the patients before and after 
the treatment, both genetically and epigenetically. Multiple studies have shown the genetic 
effects of prenatal DEHP exposure, but the epigenetic changes associate with it has only been 
covered in a few studies. The exploration of DEHP’s epigenetic effects, particularly in its target 
organs and surrogate organs such as blood, can cast light on the faster detection and better 
prognosis of DEHP exposure in human body. Based on the aforementioned observations and 
problems, in this dissertation I present three studies on the epigenetic effects in head and neck 
cancer and DEHP exposure. 
In Chapter 2, we describe the genome-wide 5hmC profiles in HNSCC by HPV status and 
subtype in 18 HPV(+) and 18 HPV(-) well-characterized tumors. As described above, 5hmC is 
an oxidative derivative of DNA methylation and an important epigenetic marker in many cancer 
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types, but its heterogeneity among HNSCC subtypes, has not been studied. We show significant 
genome-wide hyper-5hmC in HPV(-) tumors, with both promoter and enhancer 5hmC able to 
distinguish meaningful tumor subgroups. We also identify specific genes whose differential 
expression by HPV status is driven by differential hydroxymethylation. Among the previously 
reported two HPV(+) subtypes, IMU (stronger immune response) and KRT (more 
keratinization), the IMU subtype revealed hyper-5hmC and up-regulation of genes in cell 
migration, and hypo-5hmC with down-regulation in keratinization and cell junctions. We 
experimentally validate our key prediction of higher secreted and intracellular protein levels of 
the invasion gene MMP2 in HPV(-) oral cavity cell lines. 
In Chapter 3, we genetically and epigenetically characterize the immune response of oral 
cavity cancer patients from a randomized phase II trial conducted of the IRX-2 regimen, a 
homologous cell-derived complex containing a multi-cytokine biologic with multifaceted 
immune modulatory effects. The treatment regimen consists of 10 days of regional perilymphatic 
IRX-2 cytokine injections and daily oral indomethacin, zinc and omeprazole (Regimen 1) 
compared to the identical regimen without IRX-2 cytokines (Regimen 2). We elucidate changes 
before versus after the IRX-2 treatment in key immune response genes and explore the 
methylation profile change in both regimens during the treatment. Specific benefits in the tumor 
microenvironment of the cytokine cocktail in IRX-2 may include increased CD8+ T cell density, 
a slight global and repetitive element re-methylation of the genome, upregulation of the tumor 
suppressor DMBT1, and unchanged PD1/PDL1 for the subset of patients showing immune cell 
infiltration.  
In Chapter 4, we use an established mouse model to study the effect of perinatal DEHP 
exposure on the DNA methylation profile in liver (a primary target tissue of DEHP) and blood (a 
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common surrogate tissue) of both juvenile and adult mice. Dysregulation of epigenetic 
modifications, including DNA methylation, have been shown to be an important mechanism for 
the pathogenic effects of prenatal exposures, including phthalates. Despite exposure ceasing at 3 
weeks of age (PND21), we identify thousands of sex-specific differential DNA methylation 
events in 5-month-old mice, more than those identified at PND21, both in blood and liver. Only 
a small number of these differentially methylated cytosines (DMCs) are overlapped between the 
time points, or between tissues (i.e. liver and blood), indicating blood may not be an appropriate 
surrogate tissue to estimate the effects of DEHP exposure on liver DNA methylation. As part of 
the Toxicant Exposures and Responses by Genomic and Epigenomic Regulators of Transcription 
(TaRGET II) Consortium, this study implicates the usage of surrogate tissue instead of target 
tissue in human population-based studies and identifies epigenetic biomarkers for DEHP 
exposure. 
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 Chapter 2 
5-hydroxymethylation Highlights the Heterogeneity in Keratinization and Cell 
Junctions in Head and Neck Cancers 
 
This work has been published as:  Liu, S., de Medeiros, M. C., Fernandez, E. M., Zarins, 
K. R., Cavalcante, R. G., ... & Sartor, M. A. (2020). 5-hydroxymethylation highlights the 




 Head and neck squamous cell carcinoma (HNSCC) includes tumors in the oral cavity, 
larynx, and oropharynx, and is the sixth most prevalent cancer worldwide(30,31). Globally, 
HNSCC affects approximately 680,000 patients every year, with a five-year survival rate ranging 
from 37% to 62%(33). While tobacco and alcohol consumption are long-recognized risk factors, 
high-risk strains of human papillomavirus (HPV), in particular HPV-16, account for an 
increasing number of cases(35). HPV(+) HNSCC patients generally show better therapeutic 
response, improved prognosis and higher overall survival(53–55). At the molecular level, the 
gene CDKN2A (p16) is a marker for HPV etiology, due to its high expression level in HPV(+) 
tumors and common loss in HPV(-) tumors(56). A few studies have examined molecular inter-
tumor heterogeneity and identified subtypes of HNSCC (60,61), with the characteristic 
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differences in global gene expression profiles between HPV(+) and HPV(-) tumors and among 
subtypes now established. Results point to differences by HPV status and tumor subtypes in 
several carcinogenic pathways, including basal epithelial-to-keratinocyte proliferation, immune 
response, cell adhesion and induction of DNA damage, that often correlate with clinical 
outcome. 
Epigenetic differences between normal and HNSCC tumor tissue are extensive, as shown 
by genome-wide DNA methylation studies(36–38). HPV(+) status is associated with 
hypermethylation in the promoter of several specific genes(119), and HNSCC subtypes have 
been identified using DNA methylation data from The Cancer Genome Atlas (TCGA)(120). 
Previously, we showed that HNSCC DNA methylation profiles correlate with both patient diet 
and survival(119,121) and extensive genome-wide DNA hypomethylation in HPV(-) compared 
to HPV(+) squamous cell carcinoma (SCC) cell lines(122), which has since been validated by 
others in HNSCC tumors(123).  
Most of the above epigenetic data relied on bisulfite treatment of DNA, which does not 
distinguish between methylation (5-methylcytosine or 5mC) and hydroxymethylation (5-
hydroxymethylcytosine or 5hmC). TET (ten-eleven translocation) proteins can oxidize 5mC to 
5hmC and other oxidative derivatives, with 5hmC being the most abundant form in vivo(124–
126). This conversion results in a loss of transcriptional repression in promoters or enhancers, 
and is a common mechanism to activate genes in differentiation and development(127). Recent 
studies found that 5hmC is depleted in human cancers of many different origins(24,128,129), yet 
a recent study of oral cancers found that globally elevated 5hmC is positively associated with 
more aggressive tumors and worse survival(130). Genome-wide 5hmC profiles in HNSCC and 
 18 
in specific tumor subtypes remain uncharacterized, and virtually nothing is known regarding the 
association of oncogenic viruses such as HPV with 5hmC levels. 
Here, we capture genome-wide hydroxymethylation profiles and examine their 
heterogeneity among 18 HPV(+) and 18 HPV(-) previously well-characterized HNSCC tumors. 
We previously characterized two distinct HPV(+) HNSCC subtypes based on gene expression 
and copy number variation for these 36 tumors and those from TCGA(60). The IMU subtype is 
identified by a heightened immune response and more mesenchymal differentiation, whereas the 
KRT subtype is identified by more keratinization and viral integration events. Based on 
differential 5hmC profiles in other human cancers and the fundamental distinctions between 
HPV(+) and HPV(-) HNSCC, we reasoned that HPV infection would induce changes in 
hydroxymethylation, especially near differentiation and developmental genes, and corresponding 
genes differing by HPV status or tumor subtype. Specifically, since 5hmC levels are higher in 
more differentiated cells and lower in stem-like cells(131), we hypothesized an overall higher 
5hmC level in HPV(-) tumors, since they tend to be more differentiated. Additionally, we 
predicted differential 5hmC to exist between the IMU and KRT subtypes. 
We used hydroxymethylated DNA immunoprecipitation sequencing (hMeDIP-Seq) to 
assess 5hmC in our tumor cohort, and integrated results with previously generated RNA-seq data 
from the same tumors(132,133). Results pointed to extensive differential hydroxymethylation 
both by HPV status and HPV(+) subtype. The 5hmC levels at both promoter and enhancer 
regions distinguish meaningful tumor subgroups and associate with survival. We found a strong 
positive correlation between hydroxymethylation and gene expression. By integrating 5hmC 
with gene expression, we detected important pathways enriched in comparison based on HPV 
status and subtypes, including keratinization and cell junctions. Finally, we found that a much 
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higher portion of hyper-hydroxymethylated regions for HPV(-) samples fall in keratinocyte 
enhancer regions compared with HPV(+) samples. Since some of these enhancers can be linked 
to differentially expressed target genes, this result indicates that both promoter and enhancer 
hydryoxymethylation play important roles in HNSCC gene regulation. Our results partially 
explain different mechanisms responsible for previously noted subtype differences and suggest 




2.2.1 Patient recruitment and hMeDIP-seq protocol 
From 2011 to 2013, we identified 36 incident HNSCC patients with pre-treatment 
oropharynx or oral cavity squamous cell carcinoma at Michigan Medicine Hospital. HPV status 
was determined based on p16 staining and RNA-seq, as previously described(50,60). The details 
of tumor tissue acquisition can be found in Additional file 1: Supplementary Methods. After 
DNA extraction, the quality of the 36 DNA samples was measured by TapeStation genomic 
DNA kit (Agilent, Santa Clara, CA), followed by quantitation assessment by Qubit broad range 
dsDNA (ThermoFisher, Carlsbad, CA). Enzymes, PCR primers and indexed adaptors were 
supplied by New England BioLabs (Ipswich, MA) and Integrated DNA Technologies 
(Coralville, CA), respectively.  
A total of 1μg of genomic DNA was used for shearing, blunt-end repair and 
phosphorylation process, and a single adenine nucleotide was then added to the 3’ end of the 
resulting fragments for ligation preparation. DNA was cleaned by Qiagen’s MinElute PCR 
purification columns (Qiagen, Germantown, MD). DNA samples were denatured and 
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resuspended in ice-cold immunoprecipitation buffer after the addition of DNA spike-ins for 
hMeDIP (Diagenode Denville, NJ). At this stage, 10% volume of the DNA solutions were kept 
as inputs, and immunoprecipitation overnight at 4°C with rotation was performed on the 
remaining solution, after adding a 5hmC-specific antibody (Cat # 39791, Active Motif, Carlsbad, 
CA). The 5hmC-enriched DNA fragments (IP) were released from the antibody and cleaned-up 
by Proteinase K (ThermoFisher, Carlsbad, CA) and AMPure XP beads (Beckman Coulter, Brea, 
CA), respectively. In order to evaluate the percent enrichment over input in the IP, qPCR with 
primers for spike-ins was conducted. For samples with good percent enrichment over input, PCR 
amplification was performed for library production, followed by cleaning with AMPure XP 
beads and quantification with the Qubit assay (ThermoFisher, Carlsbad, CA) and TapeStation 
High Sensitivity D1000 kit (Agilent, Santa Clara, CA). Each hMeDIP-seq sample with paired 
input was sequenced on a single lane of an Illumina HiSeq 2500, generating single-end, 50 bp 
reads.  
2.2.2 hMeDIP-seq data analysis and peak finding 
The main analysis steps were conducted using the Methylation Integration (mint) 
pipeline(134). Sample quality was first assessed with FastQC(135), then reads were aligned with 
bowtie2(136) after adapter and quality trimming with Trim Galore!. Peaks for each sample 
compared to input, i.e. the genome-wide regions of hydroxymethylation, were identified using 
MACS2.  
Differential peaks, i.e.  differentially hydroxymethylated regions (DhMRs) between 
HPV(+) and HPV(-) samples, or between HPV(+) subtypes, were identified using PePr(137). 
PePr takes replicates into account using a negative binomial model while improving variability 
estimates using information from neighboring sites. Differential peaks were called with false 
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discovery rate (FDR) < 0.05 and fold change (FC) > 2. Peaks were annotated using the R 
Bioconductor package annotatr(138). Peaks annotated to X and Y chromosomes were excluded 
to avoid confounding by sex. The overall 5hmC levels over gene bodies were calculated using 
MACS2 peaks with metaGeneProfile function in HOMER(139). 
2.2.3 Principal component analysis (PCA) and singular value decomposition (SVD) analysis 
PCA was performed using prcomp function in R, with the use of hMeDIP-seq counts in 
proximal promoters, gene bodies and custom enhancer regions. X and Y chromosome reads were 
removed to avoid sex bias. The bedtools intersect function was used to obtain 5hmC counts in 
promoter regions (1kb before to 1kb after TSS’s) and gene bodies (from TSS to TES), followed 
by normalization by manual specification of library sizes in DESeq2, with the input values as 
covariate. The background was taken into account by calculating the log2 fold change for each 
region. SVD analysis was performed on the top principal components using the Bioconductor 
package ChAMP(140), to study correlation with variables of interest.  
2.2.4 Tumor tissue acquisition 
With written informed consents from patients and approval from University of Michigan 
Institutional Review Board, pretreated tumor tissues were collected for these patients, stored and 
flash frozen in liquid nitrogen at -80C. For each sample, H&E slides were prepared before 
passing the assessment criteria of at least 70% cellularity and less than 10% necrosis. Surface 
scrapings were then extracted from the tissue region where at least 70% tumor cellularity was 
confirmed while remaining frozen, followed by processing with Qiagen AllPrep 
DNA/RNA/Protein Mini Kit (Valencia, CA, USA) as per manufacturer protocol. 
2.4.5 Determination of important genes in differential 5hmC analysis 
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The genes that are important in differential 5hmC analysis are those with highest number 
of DhMRs, those with the most significant DhMRs, those with DhMRs on promoters, and those 
that are related to cancer, especially HNSCC. A list of cancer-related and HNSCC-related genes 
were downloaded from COSMIC(141). 
2.2.6 Generation of custom enhancer definitions 
We defined a consensus set of human distal enhancers (>5kb from a TSS) from a 
combination of sources for enhancer locations and links to their target genes. The definition was 
based on enhancers from DNase hypersensitive sites (DHSs) from 125 cell types processed by 
ENCODE(142), distal and non-promoter DHS within 500kb of the correlated promoter DHSs 
from 32 cell types and FANTOM5(143). All enhancer regions were extended up to 1kb around 
their midpoint. To identify target genes, we used enhancer and gene interactions (<5kb from 
TSS) identified by ChIA-PET2(144) in 13 ChIA-PET datasets(145,146) from 6 cell lines.  
2.2.7 RNA-seq analyses and association with 5hmC 
RNA-seq data from the same 36 HNSCC samples as for hMeDIP-seq was downloaded 
from GEO (accession number GSE74956)(60). The raw sequences were aligned to hg19 using 
Tophat2 v2.0.11(147), and gene expression count data were generated with HTSeq(148). 
Differential expression levels were compared both by HPV status and by HPV(+) subtypes using 
edgeR-robust, as described in (149). HPV status was previously determined by viral gene 
expression; briefly, samples with more than 500 read pairs aligned to any high-risk HPV genome 
were classified as HPV(+)(60). When comparing gene expression with 5hmC levels, for each 
identified DhMR by HPV-status, we calculated the log fold change (logFC) of 5hmC level as log 
HPV(+) / HPV(-), so that one gene corresponds to one gene expression logFC value and one or 
multiple 5hmC logFC values. The odds ratio (OR) of 5hmC logFC and gene expression logFC 
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was calculated with a standard 2x2 contingency table containing the number of sites in each 
quadrant of Figure 3A. 
2.2.8 Gene set enrichment testing on hmeDIP-seq and RNA-seq data 
RNA-Enrich(150) was used for enrichment analysis on RNA-seq results, with the 
directional analysis option so that enrichment of gene sets in HPV(+) and HPV(-) samples could 
be distinguished.Gene Ontology (GO) term and pathway enrichment analysis for 5hmC peaks 
was conducted using the gene set enrichment program for genomic regions, ChIP-Enrich(151). 
The enrichment analysis on DhMR peaks was performed using the nearest TSS locus definition 
in ChIP-Enrich, and significant pathways were marked with an FDR < 0.1. Only “enriched” GO 
terms were selected for follow-up analyses. Broad GO terms with more than 1,500 genes were 
removed to keep the results more specific.  
2.2.9 Keratinocyte enhancer regions download and analysis 
ChromHMM(152) tracks of Primary Normal Human Epidermal Keratinocytes (NHEK) 
were downloaded from the UCSC Genome Browser, and the subset of regions overlapping 
between the ChromHMM track (strong enhancer, weak enhancer, active promoter and weak 
promoter regions only) and DhMRs by HPV status were identified using the GenomicRanges 
Bioconductor package. NHEK super-enhancers were defined using ROSE (Rank Ordering of 
Super-Enhancers)(153,154), and were downloaded from DbSUPER(155). NHEK ChIP-seq data 
for 9 histone marks (H3K27ac, H3K37me3, H3K36me3, H3K4me1, H3K4me2, H3K4m3, 
H3K9ac, H3K9me1, H4K20me1) were downloaded from ENCODE. The overall 5hmC levels 





2.3.1 Widespread differential hydroxymethylation between HPV(+) and HPV(-) tumors 
The HNSCC cohort consisted of 18 HPV(+) and 18 HPV(-) patients, as previously 
determined based on RNA-seq alignment to 14 known high-risk HPV genomes. The cohort 
consisted of 26 males and 10 females, with an overall median age of 57 years. A total of 14 of 
the 18 HPV(+) patients were infected by subtype HPV16, and most were former or current 
smokers. hMeDIP-Seq was performed on these 36 HNSCC tumors to define their genome-wide 
hydroxymethylation signatures, examine how they differed by HPV status and tumor subtypes, 
and assess their relationship with clinical variables.  
All 36 samples resulted in sufficient quality of data and hundreds of thousands of 
identified 5hmC peaks, with the sequencing depth ranging from 67.7 to 152.3 million reads 
mapped. The number of peaks detected generally ranged from 208,000 to 480,000. As expected, 
the number of peaks was positively correlated with the total number of reads mapped. There 
were no significant differences between HPV(+) and HPV(-) tumors based on peak numbers (p-
value = 0.355, Wilcoxon signed-rank test), even after accounting for millions of reads mapped 
(p-value = 0.287, ANOVA test).  
In general, a much higher level of hydroxymethylation (hyper-5hmC) was reported in 
HPV(-) HNSCC. Enrichment of 5hmC levels was plotted over gene bodies, and we observed a 
consistently higher level of 5hmC in gene bodies across the genome in HPV(-) tumors (Figure 
2.1A). Consistent with previous studies, the average gene body profiles revealed a dip around the 
transcription start site (TSS) and transcription end site (TES) regions(156). 
A total of 19,398 differentially hydroxymethylated regions (DhMRs) were detected as 
hyper-5hmC in HPV(-), as opposed to only 2,316 in HPV(+) tumors (p-value < 10-5). Most 
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differential peak widths were narrow, between 100 - 200bp, and HPV(-) DhMRs were slightly 
longer than those for HPV. Although fewer peaks were hyper-5hmC in HPV(+) samples, they 
were in general stronger than the HPV(-) DhMRs, with larger fold change (Figure 2.1B). 
Of the 2,316 DhMRs in HPV(+) tumors, about 46% were annotated to genes, with the 
majority in introns. Of the 19,398 DhMRs in HPV(-) tumors, more than 72% were annotated to 
genes, also with the majority in introns. By comparing the distribution of HPV(+) and HPV(-) 
DhMR annotations to the annotations of random genomic regions, we found a significantly 
higher proportion of DhMRs were in exons (5.34%) and introns (52.77%) in HPV(-) samples, as 
opposed to a smaller percentage in exons (2.32%) and introns (33.98%) for HPV(+) DhMRs 
(Figure 2.1C). Together, these results suggest that HPV positivity in HNSCC is linked to a 
reduced hydroxymethylation signature both in and around genes. 
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Figure 2.1 The level and distribution of hydroxymethylation varies by HPV status. 
(A) Global 5hmC distribution pattern over gene bodies in both HPV(+) and HPV(-) 
samples.  
(B) Violin plot of 5hmC logFC in HPV(+) tumors (left) and HPV(-) tumors (right). The 
number on top indicates the total number of peaks being tested. Wilcoxon signed-rank 
test p-value < 10-16. (C) The distribution of hyper-5hmC peaks from HPV(+) and HPV(-) 
samples, where first column represents the combination of HPV(+) and HPV(-) tumors. 
The table on the right displayed the p-values from Fisher’s exact test between HPV(+) 
and HPV(-) HNSCC, where exons and introns showed a p-value of 10-12 and 10-16 
respectively. 
 
2.3.2 Genes and pathways with hyper-5hmC in HPV(+) tumors 
A total of 623 genes were associated with hyper-hydroxymethylation in HPV(+) tumors. 
CDKN2A (p16), the most important biomarker of HPV status in clinical tests(157),  had one of 

























5hmC in promoter regions of HPV(+) tumors. As a prime example, 5hmC was enriched at the 
CDKN2A promoter in HPV(+) cases compared to HPV(-), a difference that was independent of 
copy number variations since this is controlled for by the use of input references. This is 
important, since loss of the CDKN2A locus is known to occur in HPV(-) cases. The raw 
coverage depth by sample and peak signal values of CDKN2A both showed great deviation in 
the promoter and along the gene body between HPV(+) and HPV(-) tumors. 
Pathways enriched with higher 5hmC in HPV(+) HNSCC included desmosome, 
activation of NF-kappaB-inducing kinase activity, oxidoreductase activity, and mesenchymal 
cell differentiation (FDR<0.1). Mesenchymal development associated with epithelial to 
mesenchymal transition (EMT) is consistent with the higher risk of distant metastasis in HPV+ 
HNSCC. A total of 27 genes displayed higher 5hmC in HPV(+) tumors in mesenchymal cell 
differentiation and development, including the key EMT genes SNAI2, BMP2, SMAD2 and 
TGFB2, which are part of the TGFβ / Bone Morphogenic Protein (BMP) signaling 
pathway(158,159).  
2.3.3 Genes and pathways with hyper-5hmC in HPV(-) tumors 
A larger number of genes, 5,584, were found to be hyper-hydroxymethylated in HPV(-) 
HNSCC, of which 372 genes contained at least one promoter region DhMR. Some of the most 
important genes with promoter DhMRs were BCAR1, which plays crucial roles in metastasis and 
cell adhesion, and MMP2, which functions in EMT and immune response in multiple cancer 
types. We found 204 genes to harbor more than 10 HPV(-) hyper-5hmC regions. CDH13, a gene 
encoding a member of the cadherin superfamily that functions in cell-to-cell adhesion and is 
involved in several diseases, had 83 DhMRs. The peak signal values over each DhMR indeed 
demonstrated a higher level of hydroxymethylation in HPV(-) compared with HPV(+). 
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Pathway enrichment results identified cell morphogenesis, cell death, cell motility, and 
cytoskeletal rearrangement / cell-cell junction being among the significantly enriched 
(FDR<0.1). Several previously verified HNSCC-related genes were in a top enriched pathway. 
For example, frequently mutated HNSCC genes ERBB2, FGD1, NOTCH1, NR4A2, SEMA3E 
and ARAP3 had HPV(-) DhMRs in cell morphogenesis, and other head and neck-relevant genes 
such as CTGF, PKN2, TERT, TGFBR2 and TP63 in signal transduction had DhMRs.  
2.3.4 Main sources of heterogeneity in hydroxymethylation in promoter and enhancer 
regions  
We next sought to understand the sources of 5hmC heterogeneity in our cohort using 
principle component analysis (PCA). Interestingly, the greatest source of heterogeneity in 
promoter 5hmC profiles did not distinguish HPV(+) from HPV(-) tumors, but rather one subtype 
of the HPV(+) tumors (IMU) from all other tumors (see PC2 in Figure 2.2A, 2.2C). Consistent 
with the findings in Zhang, et al(60), the KRT subtype groups closer with HPV(-) HNSCC, 
partially due to the shared similarities of heightened keratinization. We thus sought to determine 
which, if any, known variables could explain the top PCs among HPV(+) tumors. Correlations 
between the top principle components and clinical, demographic and batch information, were 
calculated using singular value decomposition (SVD) analysis on proximal promoter regions for 
the 18 HPV(+) samples. PC1 was correlated with survival (p-value < 0.05), while both subtype 
(p-value < 0.01) and percentage of epithelial tissue (p-value < 0.05) were significant in PC2 
(Figure 2.2E). TILs (tumor-infiltrating lymphocytes) score and batch effect were correlated with 
PC3, while survival and recurrence (p-value < 0.01) were correlated with PC4.  
In terms of 5hmC heterogeneity in enhancer regions among the 36 tumors, a similar 
distinction between IMU and the other tumor samples was observed (see PC2 in Figure 2.2B, 
 29 
2.2D). Correlating variables with the top enhancer PCs for the 18 HPV(+) samples, survival was 
again a significant factor in PC1 (p-value<0.05), and subtype (p-value < 0.01) and epithelial 
tissue (p-value < 0.05) were again both significant in PC2 (Figure 2.2F). However, the 
separation between the HPV(+) IMU subtype and the rest was not observed for 5hmC gene body. 
Instead, SVD analysis on gene body 5hmC showed other relevant clinical features associated 
with the top PCs, including survival, lymphocyte tissue and HPV integration status. 
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Figure 2.2 Principle component analysis illustrated sources of heterogeneity in 
5hmC levels among HPV(+) HNSCC tumors. 
(A) PC2 vs PC3 for proximal promoter regions. (B) PC1 vs PC2 for custom defined 
enhancers regions showed clear separation between the IMU subtype and the rest on PC2, 
which contributed 10.5% and 13.48% of the total variance respectively. (C-D) PC1 vs 
PC2 for both proximal promoters and custom defined enhancers showed clear separation 
by subtype within HPV(+) tumors. (E-F) The SVD analysis on proximal promoters and 
enhancers demonstrated several relevant clinical variables, such as survival, percentage 
of epithelial tissue and subtype, which significantly correlated with each principle 






2.3.5 Differential hydroxymethylation and enriched pathways between the IMU and KRT 
tumor subtypes 
Compared with the IMU subtype, an overall higher level of 5hmC was observed in the 
KRT subtype across the gene bodies, which was closer to the 5hmC levels of HPV(-) tumors.  
In terms of differential 5hmC between the two HPV(+) subtypes, there were significantly more 
instances of hyper-hydroxymethylation  in the IMU subtype samples. A total of 63,859 hyper-
5hmC regions were found in the IMU subtype, compared with only 1,833 hyper-5hmC regions in 
the KRT subtype. Only 838 (1.3%) of these regions were also among those found different by 
HPV status, out of which the majority (771 peaks) were hyperhydroxymethylated in HPV(+) and 
IMU tumors. Similar to the annotation of DhMRs based on HPV status, the majority of both 
IMU and KRT DhMRs were mapped to. Interestingly, cancer genes CDH13 and BCAR1 were 
found with multiple KRT DhMRs, and they were also important genes for hyper-5hmC in 
HPV(-) tumors, which is consistent with the previous finding that the KRT subtype shares more 
similarities with HPV(-) HNSCC.  
The top enriched pathways marked by hyper-5hmC in the IMU subtype include 
cornification, epidermis development, keratinocyte differentiation, keratinization and cell 
differentiation. For the KRT subtype, cornification and keratinocyte differentiation also appear in 
the top enriched pathways. However, multiple pathways relevant to cytoskeleton organization or 
cell-cell junction, including cell adhesion and cytoskeleton structure, were found only in the 
KRT subtype, and were within the top 20 enriched terms. These terms were also significantly 
hyper-hydroxymethylated in HPV(-) compared to HPV(+), further explaining the similarity of 
the HPV(+) KRT subtype to HPV(-) HNSCC.  
2.3.6 Hydroxymethylation is highly associated with gene expression in HNSCCs 
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RNA-seq data on the same 36 HNSCC samples were previously analyzed, resulting in 
1887 up-regulated and 1644 down-regulated genes in HPV(+) samples (FDR<0.05 and absolute 
fold change>2) (60,160). A clear pattern of association can be observed between gene expression 
and 5hmC (Pearson’s correlation coefficient = 0.62; odds ratio (OR) = 64.5) (Figure 2.3A), 
suggesting that 5hmC likely drives many of these observed differences. This positive correlation 
still holds when comparing gene expression with 5hmC logFC at enhancer, promoter, and gene 
body separately, with gene body regions showing the strongest correlation (Pearson’s correlation 
coefficient = 0.53). The majority of genes (61.4%) are upregulated and hyper-hydroxymethylated 
in HPV(-) tumors, such as cell adhesion genes (including CDH13, CDH11, CDH2, CD44, GLI2, 
COL4A6), immune response genes (including TGFBR2, CD109, BCAR2, TIMP2, MMP2) and 
keratinization genes (CDH13, CD109, CDR, PALLD). In particular, TIMP2 and MMP2 also 
function in tumor invasion. 
For CDKN2A, we determined that differential 5hmC was especially prominent in a 5kb 
region 5’ of the second exon (chr9:21975000-21980000). To assess the association of this 
particular region with CDKN2A expression, we calculated 5hmC coverage per sample and found 
that 5hmC at this single region explained half of the variability in CDKN2A gene expression 
levels among the samples (Pearson’s correlation coefficient = 0.7). (Figure 2.3B). 
We next sought to determine the extent to which hydroxymethylation in promoter regions 
explained differences in gene expression. Twenty genes had at least one hyper-5hmC region in 
HPV(+) compared to HPV(-) in their promoter region, after excluding very low expressed genes. 
The expression of these genes was indeed significantly higher in HPV(+) IMU than HPV(-) 
samples (ANOVA p-value = 0.00066) (Figure 2.3C). The distinction between HPV(+) and 
HPV(-) samples was particularly clear for CDKN2A (Figure 2.3D). On the other hand, 296 
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genes had at least one hyper-5hmC region in HPV(-) in the promoter. However, there was no 
significant distinction found in the expression of the top 20 of these genes in any of the three 
comparisons (Figure 2.3C), leading us to hypothesize that the upregulation of genes due to 
hyper-5hmC in HPV(-) tumors is due to differences at enhancers rather than promoters. By using 
the genes with hyper-5hmC peaks on the promoter regions, we built networks using the shortest 
paths. The result showed that p16INK4 (CDKN2A) and p14ARF (alternate reading frame 
protein product of the CDKN2A locus) are the two center nodes for HPV(+) samples, while 
SMAD3, ABCC2 and IL32 are center nodes in the HPV(-) network. 
Overall, we identified 35 GO terms both enriched with differential hydroxymethylation 
(whether proximal to the promoter or distal elements) and differential expression between 
HPV(+) and HPV(-) samples (Figure 2.3E). Twenty-five of these 35 GO terms were upregulated 
and hyper-hydroxymethylated in HPV(-) samples, including adherens junction, cell 
morphogenesis, chemotaxis and Ras signaling. This finding suggests that the higher expression 
of cell junction genes in HPV(-) tumors is at least partly regulated by hydroxymethylation. It also 
suggests that HPV infection could impact many cell junction biomarkers via the active 
demethylation process.  
Next, we explored the enriched pathways based on HPV(+) subtype, finding 38 GO terms 
with significant hyper-5hmC and up-regulation in the IMU subtype, including cell migration, 
phosphorylation, MAPK cascade and cytokine-mediated signaling pathways. Conversely, there 
were 11 GO terms with significant hyper-5hmC and up-regulation in the KRT subtype, including 
cell-cell junction, keratinization and epidermal cell differentiation, which is consistent with the 
more differentiated nature of the KRT subtype. 
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Figure 2.3 5hmC in HNSCC is highly correlated with gene expression. 
(A) Scatterplot showing the positive correlation between gene expression and 
hydroxymethylation in HPV(+) and HPV(-) samples (Pearson correlation coefficient = 
0.62). The top half represents genes that are significantly up-regulated in HPV(+) tumors, 
and the right half represents genes that are significantly hyper-hydroxymethylated in 
HPV(+) tumors. (B) Scatterplot showing a strong correlation between log gene 
expression and log 5hmC of 5kb intron region (chr9:21975000-21980000) of CDKN2A. 
HPV(+) samples were concentrated near the top right corner, indicating that both their 
gene expression and 5hmC coverage were higher compared with HPV(-) samples. (C) 
Spaghetti plot of log gene expression for top 20 genes with at least one DhMR in their 
promoter region for HPV(+) IMU, HPV(+) KRT and HPV(-) samples, respectively. (D) 
Heatmap showing the expression levels of sufficiently expressed genes with at least one 
HPV(+) DhMR in their promoter, which were mostly well clustered based on HPV status 
(marked with black and grey at the top). Most genes were significantly higher expressed 
in HPV(+) samples, such as CDKN2A. ↑ indicates genes that are also up-regulated in 
HPV(+) HNSCC, and ↓ indicates up-regulation in HPV(-) tumors. Keratin and EMT 
scores are measurements of keratinization level and EMT level, and T cell signature and 
B cell signature represent degree of immune response. Generally there was a higher level 
of keratinization and EMT in HPV(-) samples, while the immune response is more 
significant in HPV(+) samples. The detailed calculation can be found in Zhang et al. (60). 
(E) Enrichment analysis results for gene expression vs hydroxymethylation by HPV 
status. Each dot represents one GO term, and the color denotes the significance (yellow: 
significant; blue: not significant). Signed p-values are defined as >0 to indicate up-
regulation in HPV(+) samples or hyper-hydroxymethylation in HPV(+) samples, and <0 






































































































































































































































































































































































































































































































































































































































































































































































































































p-value = 0.00066 
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2.3.7 HPV(-) tumors are more hydroxymethylated in keratinocyte enhancer regions than 
HPV(+) tumors 
Since 5hmC has been shown to be an important mark in enhancer regions(161), we 
revealed the distribution of hydroxymethylation across samples in relation to different chromatin 
states, including enhancers, in primary Normal Human Epidermal Keratinocyte (NHEK) cells. 
NHEK cells are isolated from the epidermis of juvenile foreskin or adult skin, and are similar to 
head and neck tissue both morphologically and physiologically(162). Around the center of 
NHEK active enhancers and weak enhancers, we observed much higher levels of 5hmC in 
HPV(-) tumors compared with both HPV(+) subtypes, although all of them showed the expected 
pattern of an increase around the enhancer centers. Enhancers also had more differences in 
hydroxymethylation than promoter regions, as indicated by strikingly more DhMRs in strong 
enhancers than in active promoters for both HPV(+) and HPV(-) tumors (Figure 2.4A, Table 
2.1). Fisher’s exact test showed an odds ratio (OR) of 2.56 (p-value < 10-16) for strong enhancers 
and 2.43 (p-value < 10-16) for weak enhancers comparing HPV(+) vs HPV(-) samples. This 
disparity between HPV(+) and HPV(-) samples is consistent with the fact that HPV(-) HNSCCs 






























































Table 2.1 Number and percentage of HPV(+), HPV(-), HPV(+) IMU and HPV(+) 




We reconfirmed the higher keratinocyte (NHEK) enhancer 5hmC levels in HPV(-) 
tumors using ChIP-seq data for the histone mark H3K4me1, a mark for active and primed 
enhancers. Visualizing the H3K4me1 signals for the top 1000 hyper-5hmC regions for HPV(+) 
and HPV(-) tumors separately, showed the highest signal value within HPV(-) hyper-5hmC 
regions (Figure 2.4B). Similar to previous findings, this trend was not observed for H3K4me1 
signals in HPV(+) tumors, indicating that HPV(-) samples have higher levels of 5hmC in 
keratinocyte enhancer regions.  
The target genes of strong enhancers with at least one DhMR were determined using 
publicly available ChIA-PET data. In order to study the impact of enhancer hydroxymethylation 
on target gene expression, we specifically focused on target genes that were also differentially 
expressed. There were 5 and 66 hyper-hydroxymethylated enhancers associated with 
differentially up-regulated genes in HPV(+) and HPV(-) tumors, respectively. In particular, 
CLDN1, a cell-to-cell adhesion gene, was the target gene of a HPV(+) enhancer DhMR, and was 
also up-regulated in HPV(+) tumors. Conversely, differentially expressed genes CDH13, 
BCAR1 and TIMP3 not only displayed HPV(-) enhancer hyper-5hmC, but also contained 
multiple HPV(-) DhMRs in their exonic and intronic regions. Multiple strong enhancers showed 




Figure 2.4 HPV(-) tumors have strong hyper-5hmC regions in epithelial and 
keratinocyte enhancer regions. 
(A) HPV(-) HNSCCs showed much higher portion of DhMRs in strong and weak 
enhancers than both random regions and HPV(+) tumors. Regions were defined using the 
ChromHMM track for NHEK cells. The number on top indicates the total number of 
peaks being tested. (B) Violin plot showing ChIP-seq log(coverage/input) values for top 
1000 HPV(+) and top 1000 HPV(-) hyper-5hmC peaks for 9 histone marks. Wilcoxon 
signed-rank test showed a p-value < 10-16 for H3k4me1 peaks. (C) UCSC Genome 
Browser view of NHEK strong enhancers near CDH13. Data shown are 5hmC profiles 
for 6 representative HPV(+) samples (upper 6 tracks) and 6 representative HPV(-) 
samples (lower 6 tracks), showing 3 regions of high 5hmC level for HPV(-). 
 
2.3.8 Expression of invasion gene MMP2 in HPV(+) and HPV(-) cell lines 
Our results show that many immune response genes, such as BCAR1, TIMP2 and 
MMP2, were both higher expressed and hyper-hydroxymethylated in the promoter and 
sometimes enhancer regions in HPV(-) tumors. In a previous study, 5hmC was shown to be 
positively correlated with depth of tumor invasion in colorectal cancer(163), and depletion of 






lines, multiple studies reported that high levels of the MMP2 protein were linked with larger 
tumor size and more tumor invasion(165). Therefore, we hypothesized that hyper-
hydroxymethylation and higher mRNA levels of MMP2 would result in higher MMP2 secreted 
protein, which can lead to stronger invasion in HPV(-) HNSCC. 
First we reconfirmed that MMP2 in HPV(-) tumors showed both higher gene expression 
and overall higher 5hmC compared with HPV(+) tumors, and there is a positive correlation 
between the gene expression and 5hmC (Figure 2.5A). Next, we assessed the secreted and 
intracellular protein levels of MMP2 in two HPV(+) oropharynx, one HPV(+) oral cavity, and 
two HPV(-) oral cavity cell lines. The zymogram results showed higher levels of secreted MMP2 
in HPV(-) cells compared to HPV(+) oropharynx cell lines, but not HPV(+) oral cavity (Figure 
2.5B). Intracellular MMP2 was also higher in the HPV(-) cell lines than the HPV(+) oropharynx 
cells (Figure 2.5C). There is no clear distinction in the MMP2 mRNA levels between HPV(-) 
oropharynx and HPV(+) oral cavity cell lines (Figure 2.5D). 
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Figure 2.5 Protein expression level of MMP2 in 2 HPV(-) and 3 HPV(+) HNSCC cell 
lines. 
(A) Scatterplot showing a correlation between log gene expression and log 5hmC of 
MMP2 gene. HPV(-) samples were concentrated near the top right corner, indicating that 
both their gene expression and 5hmC coverage were higher compared with HPV(+) 
samples. (B) Zymogram and (C) immunoblot indicated the secreted and intracellular 
level of MMP2 protein respectively. (D) Dot plot showing the mRNA level of MMP2 
with two replicates. After removing the HPV(+) oral cavity cell line, which is an outlier, 
Wilcoxon signed-rank test showed a p-value = 0.34. 
 
2.4 Discussion 
5-hydroxymethylcytosine has been shown to be depleted in various human cancers, and 
is known to be more concentrated in differentiated cells(128,131). Stem cells, which are closest 
to the basal epithelial cells in HNSCCs, are known to have lower 5hmC levels, especially in the 
gene and enhancer regions required for differentiation(132,156). For our purposes, those 
differentiation-specific regions would be epithelial and keratinocyte-specific genic and enhancer 
regions. Differences between HPV(+) and HPV(-) HNSCC are extensive in terms of prognosis, 
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tumor recurrence patterns and survival(53,55,56). Similarly, molecular studies have shown 
marked differences in gene expression, DNA copy numbers, and DNA methylation profiles by 
HPV(+) status(60,120,122). For instance, multiple studies showed genome-wide DNA 
hypomethylation in HPV(-) HNSCC tumors(123), and the differential methylation of certain 
tumor suppressor genes could be potential markers for early HNSCC diagnosis(37).  
The HPV lifecycle is tightly linked to epithelial cell differentiation, with HPV initially 
infecting the undifferentiated basal epithelial cells, and concluding its life cycle in differentiated 
keratinocytes. Upon HPV oncogene integration, heightened keratinization often occurs, 
potentially affecting metastatic risk(166). Our group has shown that patients with integrated 
HPV E6 & E7 had significantly worse overall survival(50). Unlike most cancers, evidence does 
not suggest that less differentiated HNSCCs are associated with worse survival; indeed, studies 
have suggested that more differentiated keratinocytes are associated with worse survival in 
oropharyngeal cancer(167). Due to the limited sample size of this study, we did not observe any 
significant survival difference between the two HPV(+) subtypes, where 2 and 0 deaths were 
reported after 36 months follow-up in the KRT and IMU subtype, respectively. Another recent 
publication on meta-analysis of HPV(+) OPSCC followed the observed trend of the IMU 
subtype having the best survival (labeled Cl1 in the paper) and the subtype with 100% HPV 
integration (similar to our KRT subtype; Cl2 in paper) having worse survival (62). 
Although 5hmC tends to be overall lower in cancers, others have observed lower 5hmC 
in oral cancers to actually be indicative of better prognosis(130) (Figure 2.6). This could be due 
to the confounding effect of HPV; in this study we found lower 5hmC in HPV(+) patients, who 
have less differentiated tumors and better prognosis (Figure 2.6). However, mesenchymal 
differentiation may also lead to loco-regional or distant metastasis; thus the complete relationship 
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between differentiation and metastasis appears to be complex, as suggested by studies in oral 
cancer(168). Among our differential 5hmC genes, only CDK6 was identified as a clinically 
actionable target. CDK6 was hyper-hydroxymethylated in HPV(-) tumors at seven intronic 
regions, is targeted in the treatment of certain breast cancers(169), and recently showed response 
in the treatment of oral squamous cell carcinoma(170). CD20, which is regulated by the 
epigenetic markers NFκB and SMAD2/3(171), is targeted in chronic lymphocytic leukemia and 
follicular lymphoma(172). The NFκB pathway and SMAD2/3 genes were identified as important 
5hmC markers in our study, suggesting a potential use of B cell markers in the immunotherapy 
of HNSCC. 
Our study is the first to characterize genome-wide DNA hydroxymethylation in head and 
neck cancers. Among differentiation genes, we found strong hyper-5hmC in HPV(-) tumors 
especially concentrated in cell junction and cell adhesion pathways, which is consistent with 
previous findings that HPV(-) HNSCC is more differentiated compared with HPV(+) HNSCC. 
The overall higher level of hydroxymethylation in HPV(-) HNSCCs is also consistent with 
observed overall higher levels of DNA methylation in HPV(+) oropharyngeal cancer cases, 
considering the antagonizing effect of methylation and hydroxymethylation(123). Similar to 
DNA methylation, profiles of hydroxymethylation were highly affected by HPV status, 
particularly for p16. The great majority of hyper-hydroxymethylated genes were in HPV(-) 
HNSCC, many of which play important roles in cancer pathways. CDH13, a cell-cell adhesion 
gene and a member of the cadherin superfamily, was upregulated in HPV(-) tumors and also had 
the highest number of hyper-5hmC regions in HPV(-). Interestingly, other major cadherin family 
genes, (e.g., CDH1 and CDH11), are hypermethylated in HPV(+) HNSCC(122,173). Some 
genes known to have differential methylation by HPV status also displayed differential 5hmC in 
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the opposite direction, including cell adhesion genes COL4A6 and BCAR1, and tumor 
suppressor genes TIMP3 and SFRP4. 
Even more than distinguishing HNSCC tumors by HPV status, 5hmC profiles 
distinguished the IMU HPV(+) subtype from the KRT HPV(+) subtype and HPV(-) tumors. The 
KRT subtype is more similar to HPV(-) HNSCC than the IMU subtype based on gene 
expression(60). Consistent with this, we found the same based on 5hmC, with a much higher 
level of 5hmC found in the KRT subtype, which is furthermore consistent with the more 
differentiated nature of this subtype. We also found cancer pathways such as cell migration 
enriched with hyper-5hmC in the IMU subtype, while cornification and keratinization were 
significantly enriched with hyper-5hmC in the KRT subtype. 
A recent study on hydroxymethylation of pancreatic cancer showed positive correlation 
between 5hmC and open chromatin generated ATAC-seq in both cancer and control cells(174). 
While we did not have ATAC-seq data available, in our study we found a similar correlation 
with ChromHMM tracks of NHEK cells(152), and the especially strong enrichment of 5hmC on 
enhancers in HPV(-) HNSCC could partially be attributed to its more differentiated and/or 
malignant nature.  
In summary, our comprehensive characterization of the genome-wide 
hydroxymethylation profiles in HNSCC revealed significant differential hydroxymethylation 
both by HPV status and between HPV(+) subtypes. We report the significance of CDKN2A 
hydroxymethylation by HPV status, as well as many other cancer-related genes, such as CDH1, 
TIMP3 and SFRP4. Overall, the results are closely in line with current knowledge of differences 
by HPV status, including differences in DNA methylation. We also discovered the important role 
 43 
of the less reported gene CDH13 in HNSCC, and that the differential hydroxymethylation was 
especially concentrated in CDH13 enhancer regions.  
 
 
Figure 2.6 the correlation between 5hmC level and prognosis within different tumor 
types. 
Schematic chart summarizing the correlation between 5hmC level and prognosis within 

















































 Chapter 3  
Characterization of Immune Response in Patients with Cancer of the Oral 
Cavity after Neoadjuvant Immunotherapy with the IRX-2 Regimen 
 
A manuscript covering this work is in preparation, with myself as first author, 
 
3.1 Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer 
worldwide, affecting approximately 680,000 patients every year(33,175). Traditional treatment 
of HNSCC involves a combination of surgery, radiotherapy and/or chemotherapy, and the five-
year survival rate ranges from 55% to 66%(176). Immunotherapy with immune checkpoint 
inhibitors (ICI) has shown revolutionary progress in the treatment of multiple cancers. The PD-
1/PD-L1 pathway is a key mechanism targeting T cell regulatory functions to enhance anti-tumor 
immune response(177), and PD-1 inhibitors pembrolizumab and nivolumab showed clinical 
advances in recurrent and metastatic HNSCC patients. However, the overall response rate for 
pembrolizumab is only 16% to 18% regardless of human papillomavirus (HPV) status(70,72), 
while patients treated with nivolumab have demonstrated significantly longer overall survival 
than those treated with standard single-drug systemic therapy(178). The challenge remains to 
discover how to increase these encouraging response rates and clinical results with novel 
immunotherapy approaches. 
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IRX-2 is a biologic product that contains multiple cytokines derived from normal donor 
phytohemagglutinin (PHA) stimulated mononuclear cells. The primary active components in 
IRX-2 are IL2, IL1β, IFNγ and TNFα.  Previous studies showed that IRX-2 can protect T cells 
from activation-induced cell death and promote the cytolytic functions of natural killer (NK) 
cells(179). In addition to the direct effects of IRX-2 on antitumoral immunity, IRX-2 could 
potentially prime the tumor for positive response to immune checkpoint inhibitors. In a 
completed Phase 2a clinical trial in patients with oral carcinoma, IRX-2 immunotherapy was 
associated with increased immune infiltration and chemokine receptor expression using 
multiplex immunohistochemistry (IHC) and transcriptome analysis (NanoString Technologies) 
from 7 matched pre- and post-treatment tumor specimens(180).  
Apart from the expression of immune response genes, methylation changes also play an 
important role in cancer immunotherapy. Hypermethylation at CpG islands and promoters as 
well as global hypomethylation have been documented in HNSCC in multiple studies 
(38,40,181). In particular, the hypomethylation of human retroelement long interspersed 
nucleotide element-1 (LINE-1) was associated with higher risk of oral cavity cancer (OCC) 
relapse, and is a potential predictive biomarker for OCC (182,183). In a few recent immune-
related HNSCC studies, the characterization of DNA methylation profiles predicted a 
combination of hyper- and hypo-methylation markers in response to immune checkpoint 
inhibitors (ICI), and these methylation signatures could act as surrogate biomarkers to predict 
responsiveness  to PD-1/PD-L1 inhibition (78–81). In addition, accompanied by genomics data, 
a methylation-based cell type deconvolution approach may distinguish between “immune hot” 
and “immune cold” HNSCCs (184). 
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Based on promising findings from a prior Phase 2a trial, we studied immune-related gene 
expression and genome-wide DNA methylation in tumor specimens from a larger scale 
randomized Phase 2b clinical trial. The trial was designed to determine whether IRX-2 cytokines 
induce increased lymphocyte infiltration into primary tumors in HNSCC and how these 
cytokines are active in patients with oral cavity cancer. The IRX-2 regimen started 3 weeks prior 
to surgery, consisting of an initial dose of cyclophosphamide followed by 10 days of regional 
perilymphatic IRX-2 cytokine injections and daily oral indomethacin, zinc and omeprazole 
(Regimen 1). The control regimen was identical to Regimen 1 without the IRX-2 cytokine 
injections (Regimen 2). A total of 96 patients were randomized 2:1 to Regimen 1 or Regimen 2 
(64:32). To determine the effect of IRX-2 on the expression of immune genes, a paired 
transcriptome analysis (NanoString) was conducted on pre- and post-treatment tumor samples 
from 71 patients (45 in Regimen 1 and 26 in Regimen 2). In addition, DNA methylation EPIC 
BeadChip was conducted on a subset of patients (14 in Regimen 1 and 10 in Regimen 2) to 
explore the DNA methylation profiles of patients in both arms before versus after treatment. 
 
3.2 Methods 
3.2.1 Phase 2b clinical trial 
From Jan 2016 to Jan 2018, a randomized Phase 2b clinical trial of neoadjuvant 
immunotherapy with the IRX-2 regimen was conducted on newly diagnosed Stage II, III or IVA 
oral cavity cancer patients across multiple centers in the USA and Brazil. A total of 96 patients 
were divided in two regimens, with 64 in the experimental regimen (Regimen 1) and 32 in the 
control regimen (Regimen 2). The treatment in Regimen 1 lasted 3 weeks, which included 10-
day subcutaneous bilateral IRX-2 injections in the upper neck (2 injections of 1 mL each day), an 
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initial dose of cyclophosphamide, and a 3-week course of indomethacin (25mg; 3 times daily), 
zinc supplementation (65mg/day), and omeprazole (20mg/day) (179). The treatment in Regimen 
2 was identical to that of Regimen 1 but excluded the IRX-2 (cytokine components) injections. A 
detailed study design can be found at http://www.brooklynitx.com/inspire-study/. All patients 
enrolled in this clinical trial underwent surgical resection 19 to 41 days post-randomization. This 
study was approved by the human experimentation Institutional Review Boards of the University 
of Michigan and other participating institutions. All patients have given written consent for the 
study, and the experimental methods comply with the Helsinki Declaration. 
3.2.2 Tumor sample preparation 
Formalin-fixed paraffin embedded blocks were requested from all enrolled subjects at 
each participating institution. 78 biopsy (pre-intervention) blocks and 84 surgical resection (post-
intervention) blocks were requested. From these, blocks from 24 subjects with sufficient tissue in 
both biopsy and resection were selected for DNA methylation. 
3.2.3 RNA extraction and Nanostring protocol 
Whole tumor transcriptome analysis was commercially performed by the NanoString 
Technologies (Seatle, WA) central laboratory.  Briefly, after being reviewed by a pathologist, 
formalin fixed, paraffin embedded (FFPE) slides were microdissected for RNA isolation from 
the tumor area of 5-µm slices using the High Pure microRNA FFPE Isolation Kit (Roche, Basel, 
Switzerland) or High Pure FFPE RNA Micro Kit (Roche) per manufacturer protocols. After 
being de-paraffinized with xylene and washed with ethanol, the tissues were lysed and treated 
with proteinase K for 3 hours at 55°C. After a washing step, lysates were applied onto spin 
columns and RNA was eluted once in 50 µL and twice in 40 µL elution buffer respectively. 
Next, RNA was purified and concentrated using the RNA Clean & Concentrator-5 Kit (Zymo 
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Research, Irvine, CA, USA). The yield of RNA was measured using NanoDrop 2000 (Implen 
GmbH, Munich, Germany) or Qubit RNA BR Assay Kit (Thermo Fisher Scientific) on the Qubit 
3.0 Fluorometer (Thermo Fisher Scientific), and RNA quality was determined on a Lab-on-a-
Chip 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). No sample was excluded 
solely based on RNA Integrity Number (RIN), since RNA from FFPE tissues generally have 
lower quality (RIN values <2). 
A minimum of approximately 50 ng of total RNA was used to generate whole tumor 
transcriptome profiles using the nCounter platform (NanoString Technologies) and the 
PanCancer Immune Profiling Panel from matched biopsy and resection samples. The NanoString 
captures the expression of 770 genes in total, including 730 immune response genes and 40 pan-
cancer housekeeping genes. Out of 730 immune-related genes, 109 of them define 24 different 
immune cell types and populations, 30 encode known cancer/testis antigens, and more than 500 
encode critical proteins in immune response pathways.  
3.2.4 NanoString data analysis 
A total of 71 patients out of 96 (45 in Regimen 1 and 26 in Regimen 2) had usable 
Nanostring data available both before and after treatment. A minimum of approximately 50 ng of 
total RNA was used to measure the expression of 730 immune-related genes and 40 
housekeeping genes using the nCounter platform (NanoString Technologies) and the PanCancer 
Immune Profiling Panel. The expression data were code-count normalized, sample content 
normalized, and background corrected using the NanoStringNorm R Package(185). Paired tests 
with edgeR-QLF were used to conduct two types of differential analysis: before vs after 
treatment for each regimen separately, and a contrast between the change in Regimen 1 vs the 
 49 
change in Regimen 2. Significantly differentially expressed genes had false discovery rate (FDR) 
< 0.05 and fold change (FC) > 1.5.  
3.2.5 DNA extraction and EPIC BeadChip protocol 
An H&E slide from each block was reviewed by an expert pathologist (Jon B. McHugh, 
MD) for areas of >70% tumor cellularity. The corresponding areas on unstained slides were 
microdissected for DNA isolation using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, 
Germany). All DNA samples were treated with RNAse using the QIAquick Nucleotide Removal 
Kit (Qiagen, Hilden, Germany). DNA quantity was assessed using the Qubit Broad Range 
Double Stranded DNA Assay (Thermo Fisher Scientific, Waltham, MA). Quality of these 
samples was evaluated using the Nanodrop Spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA) and the Illumina FFPE QC Kit (Illumina, San Diego, CA). This kit evaluates 
quality of DNA extracted from FFPE tissues measuring through real-time PCR using the Bio-
Rad CFX96 (Bio-Rad Laboratories, Hercules, CA). Controls (positive and no template) were 
included on each plate. Average Cq (quantification cycle) values for each sample were evaluated 
for deviance from the average Cq of the positive control (Delta Cq). As recommended by 
Illumina, samples selected for methylation measurement have Delta Cq values below 5 and have 
replicate Cq values that do not diverge by more than half a unit. 
In total, 24-paired samples were selected based on quality and quantity for downstream 
processing.  Concentrations ranged from 8.2 - 146.7 ng/µL, 260/280 ratios ranged from 1.85-
2.13, and Delta Cq values ranged from -1.3 - 4.2 for final samples. 
Bisulfite conversion was performed using 350 ng input FFPE DNA with the Zymo EZ 
DNA Methylation Kit following manufacturer recommendations. To restore bisulfite converted 
FFPE DNAs to an amplifiable form for the Infinium MethylationEPIC assay (Illumina), the 
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University of Michigan Advanced Genomics Core (UMAGC) performed the Infinium HD FFPE 
Restore protocol (15014614 RevC) according to manufacturer’s instructions. The UMAGC 
generated Methylation Profiles of the restored FFPE samples using the Infinium 
MethylationEPIC Kit (Illumina) and the manufacturer’s Infinium HD FFPE Methylation Assay 
Protocol (15027310 Rev.A).  BeadChips were scanned and image data recorded by an iScan 
Reader with Methylation NXT settings.  Methylation Profiles were generated using the 
GenomeStudio (v2011.1) Analysis Software with the Methylation Module and 
MethylationEPIC_v-1-0_B4 Manifest (Illumina).   
3.2.6 EPIC BeadChip data analysis 
MethylationEPIC BeadChip assay data (Illumina, San Diego, CA) were analyzed for 24 
patients (14 in Regimen 1; 10 in Regimen 2) with both biopsy and resection samples. Raw data 
were pre-processed with functional normalization funnorm(186). A total of 17611 probes were 
removed due to failure of detection in at least 5% of samples. After dropping cross-reactive 
probes detected in 450K BeadChip and probes that map to X and Y chromosomes, a total of 
777406 probes were used for the remainder of analysis. Linear regression and eBayes function in 
the limma R package were used to call DMPs (differential methylated probes, with methylation 
difference > 10% and FDR < 0.05) before versus after treatment in a paired analysis for each 
regimen, however no probes were significantly different. The R package DMRcate(187) was 
used to call potential DMRs (differentially methylated regions, with FDR < 0.05 and methylation 
change > 10%) from DMPs.  
3.2.7 DNA methylation-based cell type deconvolution 
Cell type deconvolution analysis has been shown to perform better using DNA 
methylation data compared to gene expression. We used MethylCIBERSORT(184) with inbuilt 
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head and neck cancer signatures on the beta values of the 24 patients with EPIC BeadChip data 
to generate a methylation matrix, which was then used in CIBERSORTx(188) for cell type 
deconvolution calculation. The cell types included were cancer, CD14 (monocytes / 
macrophages / myeloid-derived suppressor cells), CD19 (B cells), CD4_Eff (CD4+ effector T 
cells), CD56 (NK cells), CD8 (cytotoxic T cells), endothelial, eosinophils, fibroblast, neutrophils 
and regulatory T cells.  
3.2.8 Determination of response to treatment 
Two types of response to treatment were calculated for each patient having the relevant 
data: clinical tumor response and immune response (based on the change in T cell counts in the 
tumor microenvironment (Table 3.1). Clinical response categorized patients into partial 
responders (PR), stable disease (SD), or progressive disease (PD) based on RECIST (Response 
Evaluation Criteria in Solid Tumors) criteria, where the effect of the therapy was evaluated from 
unbiased centralized interpretation of CT and/or MRI scans. Immune responders (IR) were 
defined as having an increase in CD8+ TIL (tumor infiltrating lymphocytes) infiltrate score of at 
least 10 cells/mm2, as previously published(189). The individual percent change in tumor size 
from clinician’s tumor measurements was also available for all 96 patients, however this was not 
used as a measure of response due to potential subjectivity and variability in clinician estimates 
in this international, multi-institutional trial. 
  Regimen 1 Regimen 2 
Immune response 
(n=33) 
Responder 15 4 
Non-responder 5 9 
Clinical response 
(n=77) 
PR 6 2 
SD 33 17 
PD 10 9 
Table 3.1 The number of patients with immune response and clinical response status 




3.3.1 Both regimens resulted in a differential pattern of immune gene expression before 
versus after treatment  
From January 2016 to January 2018, we collected clinical data and tumor specimens from 
a total of 96 patients with newly diagnosed oral cavity squamous cell carcinoma who participated 
the neoadjuvant IRX-2 Phase 2b clinical trial with IRX-2 regimen. In order to determine the 
effect of IRX-2 on immune response, we have collected the expression level of 730 immune 
response genes with NanoString on 71 patients for paired pretreatment biopsy (3 weeks prior to 
surgery) and surgical resection specimens, out of which 45 were from patients randomized to 
Regimen 1 and 26 form Regimen 2. First, we sought to understand the degree of heterogeneity 
based on signatures in our cohort using principal component analysis (PCA). Although the 
samples did not separate by treatment regimen, a major source of heterogeneity was the 
distinction between biopsy and resection, indicating treatment induced immune response change 
in both regimens. By using the log2 fold change (FC) of resection versus biopsy samples, we did 
not observe any separation based on regimen, immune response, or clinical response. 
By comparing the baseline timepoint (biopsy) to after 21 days of immunotherapy 
(resection), we elucidated changes due to the IRX-2 treatment with and without the cytokines in 
key immune response genes. A total of 51 and 79 immune response genes were found 
upregulated and downregulated respectively in the resection samples of Regimen 1, while 51 and 
56 were found upregulated and downregulated respectively in the resection samples of Regimen 
2. Among these differentially expressed genes, 69 overlapped between the two regimens, with 33 
upregulated and 36 downregulated in resection (Figure 3.1A). Some of these overlapped 
upregulated genes have been previously linked with mutations in cancer, including CD63, BCL2, 
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MME1, DMBT1, and CXCL12, while the overlapped downregulated cancer genes include 
S100A7, HRAS, MST1R, CDH1, IL1B. Noticeably, CD8A, a gene marker for CD8 T cells, was 
only upregulated in Regimen 1. 
To visualize the expression patterns of upregulated and downregulated genes in both 
regimens, we performed hierarchical clustering on the union of differentially expression genes in 
Regimen 1 and Regimen 2 (Figure 3.1B). The resulting heatmap separated upregulated genes 
from the downregulated genes, except for a few patients whose gene expression consistently 
decreased after treatment for nearly all genes. Interestingly, while the upregulated genes 
demonstrated a consistent up-regulation pattern across patients in both regimens, the 
downregulated genes were due to large decreases in expression in a subset of patients 
irrespective of regimen. No clear distinctions were observed between the two regimens or 
between the two immune response groups. 
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Figure 3.1 Immune response genes changed similarly in both Regimen 1 and 
Regimen 2. 
(A) Venn diagrams showing the total number of differentially expressed genes, the 
number of upregulated genes, and the number of downregulated genes after treatment 
that are overlapped between Regimen 1 and Regimen 2, respectively. (B) Heatmap 
showing the log2 fold change of gene expression before versus after treatment (log2FC, 
resection/biopsy) of all 153 differentially expressed immune genes in either regimen. 
Samples are ordered in columns by regimen and immune responder status, and 
hierarchical clustering was performed on genes only, which are displayed as rows. 
 
3.3.2 DMBT1 expression level showed stronger upregulation after treatment in Regimen 1 
than Regimen 2 
Comparing the changes observed after treatment between the regimens, we identified 9 
genes which displayed significantly different changes between the two regimens (Figure 3.2A). 



















with a larger change between biopsy and resection samples in Regimen 1, while the changes in 
Regimen 2 were larger for KIR3DL2, IFNA7 and CTAG1B, and only DMBT1 was upregulated 
in both regimens. The only gene that showed previous mutations in HNSCC was DMBT1, a 
potential tumor suppressor gene functioning in calcium-dependent protein binding and signaling 
pattern recognition receptor activity(190). DMBT1 was found to be upregulated in resection 
samples in both regimens, but the extent of increases was more drastic in Regimen 1 (mean of 
59.3 fold for Regimen 1 versus 19.43 fold for Regimen 2) (Figure 3.2B). Visualizing 
individuals’ DMBT1 expression across response groups, we did not observe a strong association 
between change in DMBT1 expression level with either clinical tumor response or immune 
response (Figure 3.2B) in either regimen. However, this conclusion was limited because few 
patients with NanoString data were characterized as clinical responders after this brief 
immunotherapy regimen (n=4), and only a limited number of patients (n=26) had immune 
response information available, with only three immune responders in Regimen 2. 
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Figure 3.2 A total of 9 genes showed significantly different changes after treatment 
between the two regimens. 
(A) Heatmap showing the log2 fold change (resection/biopsy) of the 9 genes whose 
difference before vs after treatment is significantly different between Regimen 1 and 
Regimen 2. (B) Box plot of the DMBT1 gene expression at biopsy and resection in the 
two regimens separately. Spaghetti plot showed the change of DMBT1 expression in 
patients of different immune response groups. 
 
3.3.3 Change of different immune signatures after treatment in both regimens 
To study the effect of IRX-2 treatment on key immune signatures, we first assessed the 
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(CD274) and PD1 (PDCD1) revealed large individual variability (Figure 3.3). The differential 
expression analysis between biopsy and resection described above revealed downregulation of 
PDL1 after treatment in regimen 2, and that this drop in expression was mainly concentrated in 
non-immune responders. Patients who were characterized as immune responders showed little to 
no change in either gene in either regimen. 
Beyond PD1 and PDL1, we examined per patient changes in interferon, cytokine, antigen 
and inflammation gene groups, which were defined in Li et al.(191) and identified as being 
important immune responders in epithelial cancers. Overall, we observed a high level of 
variability among patients, yet 25% of the genes were differential expressed between biopsy and 
resection in both Regimen 1 and Regimen 2. (Table 3.2). After separating patients by their 
respective regimen and immune responder status, we discovered that the changes in interferon 
and antigen genes were more subtle in the immune responders of Regimen 1 than Regimen 2 and 
non-responders, but this trend was not as prominent in cytokine or inflammation genes. Although 
a definitive conclusion is difficult due to the existence of a few outlier patients with extremely 
large downregulation, we found that 62% and 75% of Regimen 1 immune responders had 
increased cytokine and inflammation gene expression; only 1 of 3 Regimen 2 immune 
responders had a similar increase. 
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Figure 3.3 The expression levels of CD274 (PDL1) and PDCD1 (PD1) in both 
regimens. 
The expression levels of CD274 (PDL1) and PDCD1 (PD1) in patients (A) with and (B) 
without immune response groups of the two regimens. The immune responder groups 
showed less change in both PDL1 and PD1 expression compared non-responders and 

























































































































































































































































































































































Immune gene types interferon cytokine antigen inflammation 
Total # of genes with Nanostring data 17 30 5 18 
Regimen 
1 
# upregulated in resection 2 1 0 1 
# downregulated in 
resection 
5 6 0 2 
Regimen 
2 
# upregulated in resection 2 1 0 1 
# downregulated in 
resection 
6 7 0 2 
Total # of differentially expressed 
genes 
8 9 0 4 
 
Table 3.2 The total number of interferon, cytokine, antigen and inflammation genes 
that are found in NanoString gene list and the number of genes in each category 
that are differentially expressed between biopsy and resection samples. 
  
 
3.3.4 Higher methylation level in resection samples than baseline in both regimens 
DNA methylation was assessed using the MethylationEPIC BeadChip Assay on 24 
patients (14 in Regimen 1 and 10 in Regimen 2), to explore the changes in DNA methylation 
caused by IRX-2. The overall global methylation distribution results showed a slight overall 
increase in methylation after treatment in both regimens, and this increase was consistent across 
CpG islands, shores and shelves. The same trend was especially prominent on the LINE-1 and 
LINE-2 elements of Regimen 1 compared to Regimen 2, and it was mainly driven by the 
immune responders in both regimens (Figure 3.4A). Since the focus of this study was on the 
effect of IRX-2 on immune response, we also looked at the methylation level of the CpGs that 
fall on the promoter regions of immune response genes. In Regimen 1, the methylation level 
increase aftertreatment was more prominent in immune responders, which was not observed for 
immune responders in Regimen 2 (Figure 3.4B).  
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Figure 3.4 The average DNA methylation levels in both regimens. 
The average DNA methylation levels in both regimens at (A) LINE-1 and LINE-2 
elements and (B) immune response gene promoters. The resection samples showed 
higher DNA methylation levels than biopsy samples for almost all the comparisons, but 
the difference is more prominent in the immune responder group of Regimen 1. 
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3.3.5 Altered methylation of immune response and keratinization pathways after IRX-2 
treatment 
By comparing the methylation profile from EPIC BeadChip data before and after the 
treatment, we did not identify any differentially methylated probes (DMPs) in either regimen. 
Testing differentially methylated regions (DMRs) with FDR<5%, we identified 523 and 1 
potential hyper- and hypo-methylated regions in the resection samples of Regimen 1 
resepctively, including those mapped to immune response genes IFI27 and SPINK5 which were 
downregulated after treatment based on NanoString data (Table 3.3). Conversely, a total of 721 
and 112 potential regions were found to be hyper- and hypo-methylated respectively in the 
resection samples of Regimen 2; of genes with potential hypermethylation, CXCL14, CLEC5A, 
LAMP3, TOLLIP and IFITM1 displayed downregulation. A total of 21 potential DMRs were 
hyper-methylated in both regimens, including keratinocyte differentiation gene RIPK4, but none 
of the overlapped genes were among the immune response genes selected for NanoString. 
Pathway enrichment of the DMRs suggested cornification, keratinization and keratinocyte 
differentiation, and epidermic development and differentiation were enriched with 
hypermethylation in Regimen 1. Pathways including organ morphogenesis, epithelium 
development and embryonic development were most significant for Regimen 2 
hypermethylation, but not keratinization or cornification. 
Direction in resection Regimen 1 Regimen 2 
Hypermethylated 523 721 
Hypomethylated 1 112 
Total 524 833 
 
Table 3.3 The number of potential differentially methylated regions (DMRs) derived 
from EPIC BeadChip data that are hyper- or hypo-methylated in Regimen 1 and 
Regimen 2 separately. 
 62 
 
3.3.6 Cell deconvolution revealed lower percentage of cancer cells and higher percentage of 
T cells after treatment for immune responders 
Cell type deconvolution analysis using bulk gene expression or DNA methylation data 
has become an important tool for interpreting changes in light of potential shifts in cell type 
proportions. Recently, it was shown that cell type deconvolution is more accurate using DNA 
methylation data than gene expression data (184). Due to the uncertainty in defining immune 
responders based on any one criterion, the cell type deconvolution results provide a 
complementary perspective. To determine the effect of IRX-2 treatment on cell type proportions 
in each regimen, we performed deconvolution with MethylCIBERSORT on the 48 samples (28 
in Regimen 1 and 10 in Regimen 2) with DNA methylation data, estimating the proportions of 
11 cell types. None of the cell types were significantly different either between the two regimens 
or between biopsy and resection samples. However, we observed decreased cancer cell 
proportions as well as increased CD8+ T cell proportions in immune responders of Regimen 1, 
which was not replicated in non-immune responders or Regimen 2 patients (Figure 3.5A). The 
cell type deconvolution results for CD8+ T cells were confirmed by the high correlation between 
the estimated CD8+ T cell proportion from MethylCIBERSORT and the CD8+ T cell density 
counts performed previously on tissue microarrays (189) (Figure 3.5B). 
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Figure 3.5 Cell deconvolution using DNA methylation data revealed higher CD8 in 
immune responders of Regimen 1. 
(A) Bar plot showing the proportion of different cell types from cell deconvolution of 48 
patients in different immune response groups. (B) Dot plot indicating the high correlation 
between MethylCIBERSORT CD8 proportion and TMA density (r = 0.51). The 
MethylCIBERSORT CD8 proportion change (resection - biopsy) was also correlated 














































































































































































































































































































Our study is the first to characterize immune-related gene expression and DNA 
methylation profiles after neoadjuvant immunotherapy with the IRX-2 regimen in a randomized 
clinical trial. We identified expression changes in immune response genes during the treatment 
with both IRX-2 and control regimens. Surprisingly, the differential expression pattern was 
similar in Regimen 1 and Regimen 2, with more than half of the differentially expressed genes in 
common between the two regimens, suggesting much of the action of the complete IRX-2 
treatment protocol is due to elements other than the cocktail of cytokines. For example, one 
cytokine component in IRX-2, IL1B, was downregulated after treatment in both regimens, which 
indicated the cytokine injection did not significantly alter transcription of IL1B. However, the 
IL2 cytokine component, showed more significant change between biopsy and resection samples 
within Regimen 1 patients (Figure 3.2A), indicating a potential linkage between 21-day 
treatment of IRX-2 and higher activated CD4+ T cells and activated CD8+ T cells, which are 
major sources of IL2(192). DMBT1 (deleted in malignant brain tumor 1) is a potential tumor 
suppressor gene encoding a pattern recognition molecule that plays a key role within the innate 
immune system(193,194). Uniquely, DMBT1 was found to have more extensive upregulation in 
Regimen 1 than in Regimen 2. Previous studies confirmed the critical role DMBT1 plays in the 
interaction of tumor cells and the immune system, and downregulation of DMBT1 is thought to 
promote invasion in head and neck cancer(195,196), which could suggest modulation of tumor 
invasiveness after IRX-2 treatment in Regimen 1 in our study. However, follow-up studies are 
needed to further understand the downstream effects of DMBT1 upregulation in patients with 
oral squamous cell carcinoma. 
Cyclophosphamide, a cytotoxic and immunoregulatory element of both regimens, slows 
cancer growth by inhibiting protein synthesis mainly by cross-linking strands of DNA and RNA, 
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and has also been shown to suppress regulatory T cells (Tregs) specifically with a single low 
dose(197). Given the complexity of the complete IRX-2 regimen and unknown interactions 
among its components, it is difficult to predict a priori the exact effect it could have on PD1 and 
PDL1 expression. On one hand, if active cytokine components in IRX-2 can prime patients’ 
immune response, the expression of PD1 and PDL1 may remain stable or increase after 
treatment. Alternatively, if the IRX-2 regimen functions in a similar manner as a type of 
checkpoint inhibitor, we might expect more tumor cells to be targeted by infiltrating CD8+ T 
cells, accompanied by decreased PD1 and PDL1 expression. In our case, although we did not 
observe a clear distinction based on PD1 and PDL1 changes between the two regimens, the fact 
that PD1 and PDL1 level stayed relatively stable for immune responders in Regimen 1 showed 
that the effect of IRX-2 cytokines likely differs from checkpoint inhibitors and might be 
somewhere between restoring the immune response and stimulating T cell infiltration. Further, 
our measures did not specifically differentiate between tumor and immune cell expression of 
these biomarkers.  However, both PD1 and PDL1 expression dropped in Regimen 2, particularly 
for non-responders and for non-responders in Regimen 1, which is consistent with an effect on 
PD-1 blockade(198) suggesting that such effects might not be clinically beneficial. In prior work 
we noted increases in CD68 tumor associated macrophages associated with IRX regimen 2 
which would be consistent with such a negative effect(189). The multiplicity of interacting 
factors makes clear interpretations difficult, however the complexity of the physiologic 
concentration of cytokines in IRX-2 also make it an attractive approach to address the multiple 
immune deficits identified in HNSCC. 
Utilizing the EPIC BeadChip DNA methylation data, we were able to identify an increase 
in global methylation level after treatment in both regimens, with a more prominent trend in 
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responders of Regimen 1 and in LINE1 & LINE2 repetitive elements. Since global and repetitive 
element hypomethylation is known to be common across cancer types, this increase is shifting 
the tumor’s DNA methylation status closer to “normal”. Other publications also report the 
potential importance of PD1 / PDL methylation in the prognosis of HNSCC patients(78,199), 
however we did not observe any significant change in methylation level in or near PD1 or PDL1. 
Pathway enrichment analysis with the DNA methylation data revealed pathways linked with 
hyper-methylation after treatment in Regimen 1, including cornification, keratinization and 
epidermic development, which could point to a change in the differentiation status of oral cavity 
carcinoma(200,201). Although our immune-focused NanoString data did not allow us to assess 
keratinization gene changes, this could be a counterpoint to the benefit of IRX-2 worth studying, 
since low keratinization has been associated with higher recurrence rates and a lower 5-year 
survival rates in oral cancer patients(202). 
Previously, our group published the initial findings of this phase2b clinical trial that 
Regimen 1 resulted in higher levels of CD8+ T cell density post-treatment than did Regimen 
2(189). Our study reconfirms this finding based on more significant CD8 markers expression 
(CD8A and IL2) in Regimen 1 only and on methylation-based cell type deconvolution. However, 
our analysis also suggested that most of the observed immune pattern change beyond this and the 
PD1/PDL1 findings, did not significantly differ by regimen. The main potential benefit of IRX-2 
has been thought to be increased activation and migration of T cells from the regional lymph 
nodes into the tumor microenvironment. Direct effects of the cytokine preparation on the primary 
tumor would not necessarily be expected unless they are mediated by changes in TILs. Our 
current study focused on changes in the tumor microenvironment related to immune gene 
expression and epigenetic methylation rather than T cells. The lack of finding major changes in 
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gene expression or methylation is therefore not surprising. We found general changes associated 
with both immune modulating treatment regimens that probably reflect the non-cytokine 
components of the regimens but also encouraging findings that confirmed the T cell density 
counts previously reported with Regimen 1.  
   A main limitation of our study is the inconsistent availability of different types of 
datasets. A total of 96 patients were enrolled in the Phase 2b clinical trial, whose clinical 
characteristics and follow-up survival information were collected in a timely manner. However, 
only 71 patients had NanoString data sufficient for gene expression analysis, and only a subset of 
those (24 patients) were selected for DNA methylation analysis. A total of 26 patients had CD8+ 
T cell density measured for determining immune responder status, and clinical tumor response 
was only available in a subset of 77 patients, resulting in missing response data in a large percent 
of patients with gene expression or DNA methylation data. With gene expression analysis 
limited to NanoString data instead of full RNA-seq, our study also lacked the ability to study 
expression of other important pathways such as keratinization and differentiation status in 
general. 
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 Chapter 4  
Perinatal DEHP Exposure Induces Sex- and Tissue- Specific DNA 
Methylation Changes in both Juvenile and Adult Mice 
 
This work has been published as:  Liu, S., Wang, K., Svoboda L. K., …& Sartor, M. A. 
(2021). Perinatal DEHP exposure induces sex- and tissue- specific DNA methylation changes in 
both juvenile and adult mice. Environmental Epigenetics, Volume 7, Issue 1, dvab004 
 
4.1 Introduction 
Di(2-ethylhexyl) phthalate (DEHP) is a plasticizer (86) often found in polyvinyl chloride 
products, including medical equipment, car upholstery, food and beverage containers, and 
building materials (87). DEHP does not covalently bond to polymer chains in these products and 
is therefore likely to spread into the environment after repeated usage (88). Due to the large 
quantity and wide variety of products containing DEHP that people interact with frequently, the 
estimated range of human exposure to DEHP is 3-30 μg/kg/day (91).  
DEHP has been detected in tissues such as blood, amniotic fluid, umbilical cord blood, 
and breast milk in humans (92–95), indicating that exposure starts as early as the fetal 
developmental stage(96). As a lipophilic compound, DEHP can be absorbed through dermal 
exposure, inhalation, and oral ingestion (93,94,203). The estimated human oral absorption varies 
from 25% to 50% depending on the dosage (98,99), while absorption in rodents can be as high as 
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58% of the oral dose, but 50% is assumed on average (100). The biological action of DEHP is 
very similar to a group of chemicals called peroxisome proliferators (PPs), and liver is a primary 
target organ for the effects of DEHP and other PPs (101). Prenatal DEHP exposure in rodents 
results in elevated fatty acid metabolism, as well as peroxisome proliferation and the 
accumulation of lipofuscin granules which are implicated in hepatocarcinogenesis (102,103). 
There are multiple modes of action of DEHP in hepatocytes, including activation of peroxisome 
proliferator-activated receptors (PPARs), induction of cell proliferation, suppression of 
apoptosis, oxidative DNA damage, and inhibition of gap junctional intercellular communication 
(101). Once absorbed, DEHP and its metabolites are distributed throughout the body in the blood 
promoting its endocrine disrupting properties.  
Epigenetic modifications, such as DNA methylation, define and control cell and tissue 
development by regulating gene expression (107). For example, DNA methylation patterning of 
imprinted genes is crucial for embryonic development (109). Previous animal and human studies 
have reported that perinatal exposure to DEHP is associated with altered DNA methylation 
(110–112), with multiple studies identifying DEHP‐induced DNA hyper‐methylation (113,114). 
A recent study in human cord blood showed significant DNA methylation changes in genes 
involved in androgen and estrogen responses, and spermatogenesis following prenatal DEHP 
exposure (115). Other studies of ovaries and oocytes showed prenatal DEHP exposure disrupted 
the expression of cell cycle regulators and changed the DNA methylation pattern of imprinted 
genes in germ cells (109,116). Although liver has been identified as a primary target organ of 
DEHP, the effect of prenatal DEHP exposure on genome-wide DNA methylation patterns in 
liver has not been assessed. 
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Contrary to in vivo environmental toxicology experiments for which target tissues are 
easily obtained, human environmental epigenetic epidemiology studies often make use of easily 
obtainable sources of DNA, such as blood and saliva, to serve as surrogate readouts of epigenetic 
alterations in target tissues, such as liver and brain (204). Therefore, it is essential to determine to 
what extent alterations measured in surrogate tissues are accurate reflections of the target tissues 
both epigenetically and transcriptionally, and whether exposure-associated alterations in genetic 
and epigenetic marks are consistent or different over the course of development. The Toxicant 
Exposures and Responses by Genomic and Epigenomic Regulators of Transcription (TaRGET 
II) Consortium was launched by the National Institute of Environmental Health Sciences 
(NIEHS) to partially address this issue of linking epigenetic alterations in surrogate and target 
tissues (204).  
As part of the consortium, in this study we used an established mouse model of perinatal 
DEHP exposure to investigate the alterations in DNA methylation profiles in both liver (target 
tissue) and blood (surrogate tissue), at post-natal day (PND) 21 and 5 months of age in cohorts of 
male and female mice. We also studied the transcriptional effect of DEHP exposure by 
characterizing the gene expression profiles of the same cohort. Due to the rapid growth and 
physiologic changes mice go through from weanling (PND21) to adulthood (5-months), we 
hypothesized divergent DNA methylation patterning between the two time points, but to what 




4.2.1 Animals and dosing paradigm 
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Mice utilized in this study were obtained from a colony maintained for over 230 
generations with the Avy allele passed through the male line, resulting in forced heterozygosity 
on a genetically invariant background with 93% identity to C57BL/6J (205). Virgin a/a females 
(6–8 weeks old) were mated with virgin a/a males (7–9 weeks old), and randomly assigned to 
receive a control or DEHP-exposed diet through consumption of chow (206,207). DEHP was 
dissolved in corn oil and mixed with chow (AIN‐93G, TD.95092, Harlan Teklad) to achieve 
7% corn oil and 25 mg DEHP per kg of chow. Control animals received the same chow with 7% 
corn oil. Dams began consumption of control or DEHP diets 2 weeks prior to mating, and 
exposure was continued during gestation and lactation.  
DEHP was mixed into corn oil from Envigo to create a stock solution, and the stock 
solution was sent back to Envigo where it was mixed with the corn oil used to produce custom 
7% corn oil chow in order to achieve uniform distribution of phthalates within the chow. The 
DEHP exposure level was selected based on a target maternal dose of 5mg/kg-day, assuming that 
pregnant and nursing female mice weigh approximately 25g and eat approximately 5g of chow 
per day. This target dose was selected based on literature demonstrating obesity-related 
phenotypes in offspring that were developmentally exposed to 5mg/kg-day of DEHP (208,209). 
The resulting exposure level is estimated to fall within the range of exposures experienced by 
humans (210). This is based on amniotic fluid levels of phthalates found in humans (ranging 
from <LOD to 100.6 ng/mL) and a study in rodents that orally ingested 11 mg/kg-day of 
phthalates resulting amniotic fluid levels of 68 ng/mL (211–218).  
After weaning (PND21), pups were weighed, and all animals received DEHP-free chow 
for the remainder of the study (Figure 4.1A). Approximately 1–2 male and 1–2 female offspring 
per litter were followed until 5 months of age (the total number of animals per treatment group is 
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between 5 and 7, and the details can be found in Figure 4.1B). All animals had access to food 
and drinking water ad libitum throughout the experiment and were housed in polycarbonate-free 
cages. This study protocol was approved by the University of Michigan Institutional Animal 
Care and Use Committee (IACUC). All the experiments in this study were conducted according 
to procedures established by the NIEHS TaRGET II Consortium. 
 
Figure 4.1 Overview of the perinatal DEHP exposure study design. 
(A) DEHP exposure paradigm showing the duration of the exposure, details of the 
exposure, and times of tissue collection. (B) Bar plot showing the number of animals in 
each exposure group per tissue, age, and sex. 
 
4.2.2 Tissue collection  
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Upon euthanasia at both PND21 and 5 months of age, blood and liver samples were 
collected according to protocols established by the TaRGET II Consortium (204). Briefly, blood 
was collected by cardiac puncture into tubes with EDTA anticoagulant, centrifuged, and plasma 
was removed. Liver tissue was weighed and then separated into individual lobes, and the left 
lobe of the liver was cryo-pulverized and suspended in Buffer RLT for nucleic acid extraction 
(Qiagen, cat # 1053393). Blood and liver DNA/RNA extraction was performed using the AllPrep 
DNA/RNA/miRNA Universal Kit (Qiagen #80224).  
4.2.3 Enhanced reduced representation bisulfite sequencing (ERRBS)  
A total of 50 ng of genomic DNA was digested using restriction enzyme Mspl, and the 
digested DNA was then purified using phenol:chloroform extraction and ethanol precipitation in 
the presence of glycogen, before blunt-ending and phosphorylation. A single adenine nucleotide 
was next added to the 3′ end of the fragments in preparation for the ligation of the adapter duplex 
with a thymine overhang. The ligated fragments were cleaned, then processed for size selection 
on agarose gel. Selected fragments were treated with sodium bisulfite to convert unmethylated 
cytosines to uracils, which are then replaced with thymines during PCR amplification. These 
libraries were next cleaned up with AMPure XP beads (Product #A63880; Beckman Coulter), 
quantified using the Agilent TapeStation genomic DNA kit (Catalog #G2991AA; Agilent) and 
Qubit High Sensitivity dsDNA (Catalog #Q32850; Invitrogen). ERRBS samples were 
multiplexed, and sequencing was performed with Illumina HiSeq 4000, generating single-end, 50 
bp reads for each library.  
4.2.4 RNA-sequencing 
After RNA extraction, library preparation was conducted in two batches using KAPA 
mRNA Hyper Prep Kit with Dual Indexing Adapters (PND21 samples) and Illumina TruSeq 
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stranded mRNA Library Prep Kit (5-month samples). These libraries were cleaned up and 
quantified using the Agilent 2200 TapeStation. Sequencing on these samples was carried out on 
the NovaSeq S2 flow cell and the Illumina HiSeq 4000 respectively for PND21 and 5-month 
samples, generating 50-bp paired end reads for each library. 
4.2.5 ERRBS data analysis 
Sequence quality per sample was first assessed with FastQC (v0.11.3), then Trim Galore! 
(v0.4.5) was used for adapter and quality trimming. More specifically, low-quality bases (quality 
score lower than 20), adapter sequences (required overlap of 6bp), and end-repair bases from the 
3’ end of reads were trimmed, and all reads shorter than 20bp after trimming were discarded. 
Bismark (219) was used for alignment and methylation calling, where reads were aligned to 
mm10 genome using Bowtie2 and methylation calls were reported for all nucleotides with a read 
depth of at least 5. 
Differentially methylated cytosines (DMCs) and differentially methylated regions 
(DMRs) of 50 bp windows were identified using the methylSigDSS function of the methylSig R 
package (220,221), with significance cutoff of FDR <0.05 and an absolute difference in 
methylation of > 10%. The number of DMCs and DMRs were similar across conditions, so we 
used DMCs for all of the following results but enrichment analysis. Sufficient sequencing 
coverage for a minimum of 4 samples from each treatment group was required for the test. Batch 
effect was taken into consideration by using run number as a covariate, and sex was used as a 
covariate for combined analysis of both females and males. Sex stratified tests were also 
performed for each tissue and time point. The annotation was performed with the 
annotate_regions function of the annotatr R Bioconductor package (138). Gene set enrichment 
testing on DMRs were performed using the nearest TSS locus definition in the ChIP-Enrich R 
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Bioconductor package to find enriched pathways, and pathways with an FDR < 0.05 were 
considered significant (151). 
4.2.6 Annotation of DMCs to CTD and imprinted genes 
Genes having previous evidence of correlating with DEHP exposure were downloaded 
from the Comparative Toxicogenomics Database (CTD) (222), resulting in a list of 1186 genes 
from 1903 literature entries. A list of 316 mouse imprinted genes was generated by retrieving 
imprinted gene sets from two publications (223,224), followed by removal of the redundant 
genes. 
4.2.7 RNA-seq data analysis 
Data quality checks and gene feature summarization were conducted using the TaRGET 
II RNA-seq pipeline set by the Consortium Data Coordinating Center (DCC). Genes with  >=1 
CPM in at least 10 samples across all the consortium samples were used for normalization and 
differential analysis, which was conducted by the DCC using the RUVr function in RUVSeq 
(225) (k=3) separately for each institution’s data and DESeq2 (226), respectively. As determined 
to be optimal by the DCC, differentially expressed genes were identified with absolute fold 
change > 1.5 and adjusted p-value < 0.001. Cell type deconvolution was conducted on the RNA-
seq data of all blood samples at weanling (PND21) and adult (5-month) using CIBERSORTx 




4.3.1 Genome-wide differential methylation analysis for PND21 and 5-month mice 
To identify epigenetic changes in liver and blood induced by perinatal DEHP exposure in 
our mouse model, we focused on the effect of DNA methylation by conducting Enhanced 
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Reduced Representation Bisulfite Sequencing (ERRBS). All of the 99 samples (see Figure 4.1B 
for individual group sizes) resulted in sufficient quality of data covering 5% of all CpG sites 
across the mouse genome. The total alignment percentage ranged from 58.5% to 72.4%, and the 
average bisulfite conversion rate was 99.9%.  
When comparing differential methylation between the DEHP exposed group and the 
control group at each time point, including sex as a covariate, we found fewer changes at PND21 
(an average of 39 DMCs) than at 5 months (an average of 453 DMCs) of age for both blood and 
liver. The number of DMCs detected at 5 months was approximately an order of magnitude 
higher than those at PND21, despite DEHP exposure stopping at PND21 for the F1 offspring. 
We next tested for sex-specific methylation changes, since endocrine disruptors often 
have sex-specific effects (228). The majority of the covered CpG sites (82.75% for female and 
81.04% for male) are overlapped among the four respective groups (PND21 blood, PND21 liver, 
5-month blood, 5-month liver), indicating the CpG sites were covered comprehensively among 
all comparisons. Larger numbers of DMCs were consistently identified across time and tissues 
using sex-specific analyses, again with more significant DMCs at 5 months than PND21 (Figure 
4.2). Although the majority of differential CpG sites displayed methylation differences of less 
than 20%, we did identify some sites with more than 40% change and p-values < 10-10. 
Compared to the overall, sex-combined analyses, we observed higher numbers of both hypo- and 
hyper- methylated sites with DEHP exposure, with similar numbers of hypermethylated and 
hypomethylated CpGs (Figure 4.2). 
Annotating these sex-specific DMCs to genes and CpG islands revealed that at PND21, 
more DMCs occurred in CpG islands and shores in female blood compared with the other 
groups, and slightly higher proportion of DMCs were annotated to introns and exons in female 
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samples than male samples (Figure 4.3A,B). At 5-months, a similar but more significant trend 
was observed for higher rates of CpG island and shore DMCs in female blood (z-test p-value < 
10-4), although there was a higher proportion of DMCs annotated to introns in liver than blood in 
female samples (Figure 4.3C,D).  
To examine how much inter-individual variation can be explained by methylation, we 
calculated the methylation level of the sex-specific DMCs identified above for all samples. The 
majority of individual animals could be clearly distinguished as PND21 or 5-months of age on 
the basis of methylation percentage of DMCs in both blood and liver (Figure 4.3E,F). More 
specifically, within blood samples, PND21 and 5-month animals separate clearly in PC1, with 
significantly more heterogeneity among the 5-month animals (Figure 4.3E). This separation is 
not as obvious in liver samples in the first three principal components, due to the even higher 
variation among 5-month livers (Figure 4.3F). The PND21 subjects do not separate well based 
on treatment either in blood or liver, while there is trend of separation between DEHP and 
control groups in blood samples at 5 months. 
We identified a total of 1215 DMCs that mapped to gene promoters at PND21 (219 
DMCs mapped to 149 genes) and 5 months (996 DMCs mapped to 715 genes). We further 
prioritized these DMCs by overlapping the promoter annotated genes with genes shown to be 
correlated with DEHP exposure, as indicated in the Comparative Toxicogenomics Database 
(CTD). Out of 2024 PND21 and 10312 5-month sex-specific DMCs, 74 (3.66%) and 358 
(3.37%) were mapped on CTD genes respectively. Interestingly, DEHP was found to affect the 
mRNA expression of the Gnas gene (229), an imprinted gene in the G protein-coupled receptors 
and Ras signaling pathway. We identified promoter hyper-methylation of Gnas in the DEHP-
exposed group in both male liver and blood at PND21, and both female liver and blood at 5 
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months. The prioritized gene that had the highest methylation change in female blood at PND21 
was Ucp2, which encodes a mitochondrial uncoupling protein, and was found to be both 
hypermethylated (53.89% methylation difference) and DEHP-relevant in CTD with opposite 
direction of gene expression. We also identified 3 hypomethylated sites in the DEHP group in 
the promoter region of the Esr1 (estrogen receptor 1) gene in female liver of 5 months.  
 
 
Figure 4.2 Overview of the number of DMCs between DEHP exposure and control 
groups. 
The bar plot shows the number of hypermethylated and hypomethylated DMCs in DEHP 


























































Figure 4.3 Annotated locations of the differentially methylated cytosines (DMCs) 
and heterogeneity among the animals in blood and liver. 
(A) Stacked bar plot of 3-week (PND21) DMCs annotated to CpG islands, shores, 
shelves, and (B) regions relative to genes. (C) Stacked bar plot of 5-month DMCs 
annotated to CpG islands, shores, shelves, and (D) regions relative to genes. The “All” 
column indicates all the DMCs tested in each condition. (E) PCA plot showing the 
distribution of each individual mouse based on the methylation level of DMCs in at least 
one comparison in blood and (F) liver.  
 
4.3.2 Pathways enriched with differential methylation in DEHP exposure 
In addition to individual genes, we were interested in identifying sex-specific pathways 






























































































































































We found more enriched GO terms for 5 months (n=408) than for PND21 (n=16). After 
combining related GO terms, organ growth and morphogenesis in thymus, muscle, eye, heart and 
embryos were enriched in female blood at 5 months, together with cell-cell adhesion. In female 
liver, cellular response to estrogen stimulus, DNA binding and intracellular transport were 
significant. For male-specific pathways, cell adhesion molecule binding was enriched in blood, 
while muscle contraction, cholesterol homeostasis and organ morphogenesis were enriched in 
liver. 
4.3.3 Consistent differential methylation marks across tissues and time points 
To address the TaRGET II consortium’s aim of determining the extent to which a 
surrogate tissue (blood) reflects the changes observed in a target tissue (liver), we compared the 
DMCs from liver and blood at both PND21 and 5 months. We identified only one overlapped 
DMC in female for PND21 samples, which was near the promoter region of the Eng gene. Eng 
encodes the endoglin protein which plays an important role in the regulation of angiogenesis 
(Table 4.1). A total of 12 and 12 overlapped DMCs were detected for 5-month female and 5-
month male respectively, but only 3 and 7 of these were changed in the same direction for both 
tissues (Table 4.1). The only gene showing prior correlation with DEHP exposure from CTD 
was a glycine transporter gene Slc6a9, and it was found with hypomethylation on exon 15 in 
both male blood and liver at 5 months. These findings overall represent a low level of 
consistency in DEHP-induced differential methylation between liver and blood, and a similar 
dearth of overlap between blood and liver was reported in our lead exposure study (230). 
With the multiple differentially methylated sites and regions induced by DEHP exposure, 
we next determined which changes were consistent between PND21 and 5 months. The number 
of overlapped DMCs in the same direction between the two time points as well as their details 
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are listed in Table 4.2. Only one overlapped promoter DMC was reported, which was located in 
the Ick gene in female blood. Another overlapped DMC was identified in an intronic region of 
the same gene, and both of the CpGs were hypomethylated.  



















3 Hypermethylated chr4:153333737  intergenic 12.63; 16.47 
Hypermethylated chr16:32173514  intergenic 17.33; 16.54 
Hypomethylated chr9: 43151371 Pou2f3 intron -13.50; -20.93 
5-month 
Male 
7 Hypermethylated chr16:21402190  intergenic 10.85; 53.92 
Hypermethylated chr6:114408371 Hrh1 intron 16.27; 11.60 
Hypomethylated chrX:37950454 Rhox11-
ps2-201 
1to5kb -10.05; -25.61 
Hypomethylated chr6:116795937  intergenic -12.63; -23.13 
Hypomethylated chr13:53564366  intergenic -12.34; -14.81 





Hypomethylated chr16:93981703 Cldn14 intron -15.15; -14.91 
 
Table 4.1 Sex-stratified differentially methylated cytosines (DMCs) consistent in 
both blood and liver at PND21 and 5 months. 
Genomic locations and genic annotations are provided. The percentage of methylation 
difference was calculated as DEHP - Ctrl in blood and liver samples respectively. The 
gene marked in bold indicates prior correlation with DEHP exposure from CTD. 
 
Group # of DMCs 
overlapped  






4  Hypermethylated chr5:117054318  Gm7478-
201 
1to5kb 27.34; 25.37 
Hypomethylated chr9:78154861 Ick promoter; 
intron 
-18.20; -11.96 
Hypomethylated chr9:118764757  Itga9 intron -12.36; -18.38 
Hypomethylated chr15:102955158 Hoxc11 exon -17.39; -15.72 
Female 
liver 
1 Hypermethylated chr7:40026066  intergenic 15.70; 12.93 
Male 
blood 
3 Hypermethylated chr6:86098604  Add2 exon 39.24; 23.98 
Hypermethylated chr5:146687971  intergenic 17.55; 15.07 
Hypomethylated chr5:112269237 Crybb1 intron -15.13; -14.46 
Male 
liver 





Table 4.2 Sex- and tissue- specific differentially methylated cytosines (DMCs) 
consistent at both the 3-week and 5-month time points. 
Genomic locations and genic annotations are provided. The percentage of methylation 
difference was calculated as DEHP - Ctrl in PND21 and 5-month samples respectively. 
 
4.3.4 DNA methylation levels are higher in blood than liver at both PND21 and 5-month 
DNA methylation differences between blood and liver are relevant for determining the 
extent to which blood can be used as a surrogate for biomarkers of exposure. We investigated the 
methylation level at CpG islands, shores and shelves for all the mice tested at PND21, and the 
result showed that levels were significantly higher in blood than liver for all these regions, 
especially in CpG shores and shelves (Figure 4.4A). No clear sex-specific difference was found. 
Upon replicating the comparison for 5-month mice, we found an even more drastic difference 
between the methylation levels of blood and liver (Figure 4.4B). In both cases, no clear overall 
difference in methylation levels was observed between DEHP exposure and the control group. 
These large baseline methylation differences in blood compared to liver may contribute to the 
lack of consistent changes observed due to DEHP exposure. 
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Figure 4.4 Sex- and tissue- stratified genome-wide DNA methylation levels at CpG 
islands, shores and shelves. 
Sex- and tissue- stratified genome-wide DNA methylation levels at CpG islands, shores 
and shelves at (A) 3 weeks (PND21) and (B) 5 months. Blood shows higher DNA 
methylation levels than liver in CpG shores and shelves for both sexes, and with tissue 
differences increasing with mouse age. 
 
4.3.5 DEHP exposure impacts DNA methylation of imprinted genes 
Previous publications suggest that exposure to DEHP and other endocrine disruptors can 
profoundly alter epigenetic marks in imprinted genes (229,231,232), however the effect of 
perinatal DEHP in blood and liver specifically remains unknown. Here we compared the 
methylation level of mouse imprinted genes at CpG islands, shores and shelves, and discovered 
CpG_islands CpG_shores CpG_shelves




















































that the effect of DEHP on imprinted genes is both sex and tissue specific (Figure 4.5A,B). For 
instance, male liver showed slight increased methylation at CpG shores with DEHP exposure at 
both PND21 and 5 months, while male blood had decreased methylation at CpG shelves at 
PND21. In general, changes in imprinted gene methylation levels by DEHP exposure were more 
obvious in liver than in blood, reinforcing the sensitivity of liver as a target tissue of DEHP 
exposure.  
We found multiple mouse imprinted genes with DMCs in their promoter at both time 
points. For instance, the imprinted gene we found with the most DMCs was Gnas, which had 11 
DMCs with DEHP hypermethylation in PND21 male blood and liver, as well as 5-month female 
blood, female liver and male liver. Another important imprinted gene, Runx1, which functions in 
hemopoiesis, was found to have promoter DEHP hypomethylation in female blood at PND21, 
but with DEHP hyper-methylation in female blood at 5 months. A similar pattern was found for 
Zrsr1, a maternally imprinted gene, which showed both DEHP hyper- and hypo-methylation in 
its promoter region at both time points in female liver. Despite lack of average methylation 
change on the gene body, Igf2r was found with several DMCs in both directions of female blood, 
female liver and male blood.  
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Figure 4.5  Sex- and tissue- stratified genome-wide DNA methylation levels of 
imprinted genes at CpG islands, shores and shelves. 
Sex- and tissue- stratified genome-wide DNA methylation levels of imprinted genes at 
CpG islands, shores and shelves at (A) 3 weeks (PND21) and (B) 5 months. Blood shows 
higher DNA methylation levels than liver in CpG shores and shelves for both sexes, and 
slightly higher level of differences in liver were observed between DEHP and control 
group compared with the differences in blood. 
 
4.3.6 DEHP exposure has greater effects on gene expression at PND21 than 5 months 
To examine whether the differential methylation associated with DEHP exposure had an 
impact on gene expression at the same time points, RNA-seq data were generated using RNA 
PND21 imprinted genes




















































from the same animals. Results showed a subtle overall effect, with only a few differentially 
expressed genes identified at 5 months. At PND21, a total of 5 and 70 significant genes in male 
and female blood, respectively, and 52 and 706 in female and male liver (the total number of 
differentially expressed genes in each group are listed in Figure 4.6A). By comparing 
differential gene expression with previously identified DMCs, we did not observe any genes with 
both altered DNA methylation and change in gene expression at 5 months. However, Zfhx3, 
Sh3pxd2a, and Plec were all upregulated in the DEHP exposure group at PND21 in female liver, 
and these genes also harbored hypomethylation on the gene body in the respective group. On the 
other hand, downregulated gene Col4a2 was found with hypermethylation on exon 23 in male 
blood. In PND21 male liver, a total of 20 differentially expressed genes were found to harbor 24 
DMCs, with 1 of these genes being hypermethylated and downregulated, and 9 being 
hypomethylated and upregulated (Figure 4.6B). Two of the genes, Dnmt3a and Abca2, were 




Figure 4.6 Differential gene expression analysis on the same cohort. 
(A) Bar plot showing the number of up-regulated and down-regulated genes in blood and 
liver separately at the two time points. (B) Scatterplot showing all the DMCs that 
overlapped with upregulated or downregulated genes. The top half represents genes that 
are significantly upregulated in DEHP exposure groups, and the right half represents 
hypermethylated DMCs in DEHP exposure groups. Sites that showed opposite direction 






In this study, we used a mouse model with pre- and peri-natal DEHP exposure to assess 
resultant genome-wide methylation responses at two ages (PND21 and 5 months) using ERRBS. 
We identified sex-specific DNA methylation changes in both juvenile and adult mouse liver and 
blood linked with the DEHP exposure. We found a few hundred genes harboring DMCs in their 
promoter regions, though only one (Spata13) showed significant gene expression change of the 
opposite direction from DNA methylation. For instance, the gene Esr1 was found to harbor three 
hypomethylated sites upon DEHP exposure in the promoter region in livers of 5-month-old 
females. Interestingly, although previous studies demonstrated both positive and negative 
correlations between DEHP exposure and change in Esr1 gene expression (233–236), the two 
studies of mouse liver both suggested that DEHP exposure is correlated with an increase in Esr1 
expression. Our finding of hypomethylation, which occurred in liver but not blood, is consistent 
with the fact that the previously-observed effects of DEHP on Esr1 expression were liver-
specific and not observed in other tissues (236).  
Other interesting finding lies with the imprinted gene Gnas, which displayed promoter 
hyper-methylation in the DEHP group in both male liver and blood at PND21, and both female 
liver and blood at 5 months. As an important component in G protein-coupled receptors, Gnas 
plays a role in development of obesity and regulation of energy balance (237). Notably, Gnas 
was previously found to have differential methylation in response to many types of 
environmental exposures, including bisphenol A (238), lead (230), folic acid depletion (239), 
gases/fumes (240) and prenatal maternal stress (241), suggesting the Gnas imprinted cluster may 
be an especially labile region, sensitive to many environmental exposures. Although there was 
prior evidence from CTD showing the impact of DEHP on DNA methylation levels of imprinted 
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genes Igf2r, Peg3, and H19 in mouse oocytes (109), we did not observe any significant changes 
in DNA methylation at these genes in either blood or liver. 
Most of the differential methylation marks identified in this study were sex-specific, 
which is related to the fact that DEHP interacts with the androgen (AR), estrogen (ER), and 
PPARs, with a negative impact on testosterone production (104). Another explanation lies with 
the fact that reprogramming of post-fertilization methylation and in primordial germ cells occur 
with different kinetics and mechanisms between males and females (242). Multiple direct effects 
at the molecular level of both DEHP and its metabolites were observed in vitro by using a 
reporter assay with human cell lines on the estrogen receptor (ESR1) and on AR (97,243). In our 
study, Esr1 demonstrated sex-specific differential methylation at its promoter region, while AR 
also showed sex-specific differential methylation, but in the gene body region. PPARs also 
regulate the expression of UCPs, including Ucp2, which harbored a hypermethylated site with 
53.89% methylation difference, and previous research showed DEHP can result in decreased 
expression of Ucp2 (244).  
The differential methylation results also revealed that the number of DMCs at 5 months 
were almost 3-5 times the number of DMCs at PND21, indicating DEHP exposure early in life is 
correlated with more significant altered DNA methylation at a later stage of mouse development. 
Interestingly, significantly greater heterogeneity in methylation was observed among the 5-
month animals than PND21 counterparts in both blood and liver. One explanation could be 
increased cell type methylation heterogeneity with age after DEHP exposure, which has been 
reported in mice of various ages (245–247), but we are not able to distinguish this hypothesis 
from the effect of a few outlier individuals without single-cell analysis. Another possibility lies 
with “environmental deflection”, a toxicant-mediated shift away from the baseline rates of age-
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related methylation (248), where the deflection of DEHP could shift the methylation process 
during development. In support of DEHP causing more heterogeneity with age, we did observe 
slightly higher variance levels in the DEHP groups compared with control groups at 5 months for 
age-related CpGs (data not shown, average percentage increase of standard deviation = 5.65%). 
In particular, we identified many enriched pathways at 5 months only, in either blood or 
liver. For instance, cellular response to estrogen stimulus and regulation of intracellular transport 
were significant in female liver, consistent with DEHP’s effect on female hormones (249), while 
cholesterol homeostasis and channel activity were significant in male, and many of the 
aforementioned pathways are relevant to the action of DEHP in liver. Organ growth, 
morphogenesis, and cell-cell adhesion were enriched in female blood, suggesting the epigenetic 
effect of DEHP has potential effects on organ development and epithelial-mesenchymal 
transition (EMT) (250).  
These methylation changes, however, did not translate to differential expression at the 5-
month time point, which is in line with the finding of a recent study on endocrine disrupting 
chemicals showing that reprogrammed genes remained transcriptionally silent without any 
impact on metabolism until a later life stage (251). It may be that additional aging or an external 
stimulus leads to further differential gene expression. We did not identify many affected GO 
terms at PND21, possibly due to the lower degrees of differential methylation. We identified two 
genes, Dnmt3a and Abca2 with DEHP hypomethylation and upregulation in male liver at 
PND21. Dnmt3a is an important epigenetic modifier in embryonic development and imprinting, 
and a few previous studies re-confirmed the DEHP exposure results in increased expression 
(252,253).  Another study on low-dose pollutant mixture emphasized the association between 
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DEHP exposure and decreased expression of Abca2 (254), which is a PPAR target gene and a 
member of the superfamily of ATP-binding cassette (ABC) transporters. 
Our study did have limitations that may have resulted in missing some important 
findings. The use of ERRBS resulted in the analyzed CpG sites being biased towards CpG 
islands and shores, and other areas of higher-than-average CpG density. The technique of 
ERRBS does not distinguish 5hmC (5-hydroxymethylcytosine) from 5mC. Since we only 
focused on 5mC in this study, Oxy-RRBS would have been a more accurate measurement 
option. As the next step, we plan to analyze the methylation profile in the same cohort more 
comprehensively using whole genome bisulfite sequencing (WGBS), which captures CpG sites 
of the entire genome at single-base resolution. Due to limited resources, we did not measure the 
blood cell count before isolating DNA and RNA in our experiments, which could have ruled out 
the potential effects of blood cell type differences in the peripheral blood leukocytes between 
DEHP exposure and control groups (255). As an alternative to using the blood cell counts, we 
performed cell type deconvolution with the RNA-seq data on all the blood samples, and the 
results showed no significant difference between DEHP exposure and control groups regarding 
all cell types tested. Although this could indicate that the blood cell counts did not play a major 
role in the methylation level difference among each sex-specific group, we cannot rule out a 
slight overall shift in the percent of leukocytes. Our relatively small sample sizes when stratified 
by sex may also have resulted in missing many of the more subtle DNA methylation and gene 
expression differences, with small effect sizes at the given DEHP dosage.  
As part of the TaRGET II consortium, one of the objectives of this study was to 
determine the extent to which surrogate tissues (blood) reflect the target tissues (liver) in terms 
of DNA methylation, and whether methylation marks are consistent or different ages of animals 
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(204,256). Although hundreds to thousands of DMCs and DMRs were detected in both liver and 
blood at both PND21 and 5 months, only a few DMCs overlapped among them. For example, the 
same promoter DMC near the Eng gene was detected in female blood and liver at PND21, and 
Slc6a9 had the same hypomethylated mark between the two tissues in male at 5 months, whose 
upregulation was linked to DEHP exposure (257). Overlapped enriched pathways between liver 
and blood at 5 months included cell fate commitment, transcription factor activity and cyclic 
nucleotide metabolic process. Due to the small number of consistent marks between tissues in 
both juvenile and adult stages, we conclude that in general blood does not serve as a good 
surrogate tissue for liver, in terms of the DNA methylation profile changes due to our dose of 
perinatal DEHP exposure. However, the blood-specific methylation changes may be used as 
biomarkers for perinatal DEHP exposure. Indeed, we identified a small number of individual 
CpG sites affected in both tissues by DEHP in a sex-specific manner, which can serve as a 
starting point for targeted studies with larger  
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 Chapter 5 Discussion 
5.1 Conclusions 
In this dissertation, I have described the epigenetic effects in carcinogenesis and response 
to environment, with a particular focus on regulatory roles of DNA methylation. Although 
genetic changes during DNA replication are one of the most significant risks of cancer 
development, environmental exposures to certain chemicals, such as tobacco smoke and 
radiation, can also cause DNA damage and epigenetic changes that contribute to carcinogenesis 
(258,259). For instance, both viral infections (including HPV) and tobacco consumption (first- 
and second-hand) are examples of environmental exposure that are known to increase the risk of 
multiple cancers, including HNSCC. The effects of some carcinogenic environmental exposures 
can occur later in life. Diet, for example, is a type of environmental exposure that influence the 
risk of development cancer, and numerous studies have confirmed multiple nutritional 
compounds have epigenetic targets in cancer cells (260). Thus, the interplay between 
carcinogenesis and environmental exposures has been essential genetically and epigenetically, as 
environmental factors continue to surface as potentially instrumental in explaining various 
pathways of carcinogens in different tumor types. 
In Chapter 2, we described global 5hmC profiles and important genes with 5hmC 
changes in HNSCC both by HPV status and by HPV(+) subtype. Although 5hmC marks genes 
across a wide array of cellular processes, 5hmC profiles highlight genes turned on during 
differentiation, and can therefore be used for an in-depth characterization of the differentiation 
state of tumors. Thus, genome-wide 5hmC analysis is beneficial, especially to the extent that 
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differentiation state affects carcinogenic pathways, including cell junctions and adhesion, 
invasion, and migration in our study. Our data suggest that 5hmC profiles for the IMU subtype 
could be a useful biomarker in exploring the prognosis advantage of HPV(+) cancers and should 
be explored further. As the first study to characterize the genome-wide 5hmC profile in HNSCC, 
we identified significant genome-wide hyper-5hmC in HPV(-) tumors, with both promoter and 
enhancer 5hmC levels being clinically relevant and able to distinguish meaningful tumor 
subgroups. We also implicated 5hmC in key cancer-related processes that determine the 
likelihood of metastasis in head and neck cancer. Clinically, therapeutic de-escalation schedules 
are being introduced for HPV(+) patients, but the current challenge to such changes includes 
better identification of the small subset of HPV(+) cancer patients that have poor prognosis. Our 
study has important implications that 5hmC levels are crucial in defining tumor characteristics 
and potentially used to define clinically meaningful cancer patient subgroups for many cancer 
types. 
In Chapter 3, we captured the immune-related gene expression on a subset of oral cavity 
cancer patients during a Phase 2b clinical trial testing the effects of the cytokines in IRX-2. We 
were able to characterize the significant change of more than 100 immune-related genes in the 
control and/or treatment regimen and explore the correlation between response information and 
immune signatures. We conclude that the cytokine components of IRX-2 have definite but subtle 
effects on patient immune response, and that some of the effects of the complete IRX-2 treatment 
are due to the non-cytokine components. Specific benefits in the tumor microenvironment of the 
cytokine cocktail in IRX-2 may include increased CD8+ T cell density, a slight global and 
repetitive element re-methylation of the genome, upregulation of the tumor suppressor DMBT1, 
and unchanged PD1/PDL1 for the subset of patients showing immune cell infiltration. Future 
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studies with larger sample size and more complete data will be able to provide a more 
comprehensive picture and a better understanding of the effects of IRX-2 treatment and help in 
selecting patients most suitable for immunotherapy. 
 In Chapter 4, we used a mouse model with perinatal DEHP exposure to assess resultant 
genome-wide methylation responses at two ages (PND21 and 5 months) using ERRBS. We 
identified sex-specific DNA methylation changes in both juvenile and adult mouse liver and 
blood linked with the DEHP exposure. Although hundreds to thousands of DMCs and DMRs 
were detected in both liver and blood at both PND21 and 5 months, only a few DMCs 
overlapped among them, indicating blood does not serve as a good surrogate tissue for liver in 
terms of the DNA methylation profile changes at our dose of perinatal DEHP exposure. 
However, the blood-specific methylation changes may be used as biomarkers for perinatal DEHP 
exposure. Indeed, we identified a small number of individual CpG sites affected in both tissues 
by DEHP in a sex-specific manner, which can serve as a starting point for targeted studies with 
larger sample sizes. 
 
5.2 Application of the important epigenetic marker 5hmC in other cancer types 
 In Chapter 2, we described the importance of 5hmC in HNSCC, especially in promoter 
and enhancer regions in distinguishing HPV(+) and HPV(-) tumors. We have collected whole 
genome bisulfite sequencing (WGBS) data on the same cohort of patients, which captures both 
5mC and 5hmC. By combining WGBS and hMeDIP-seq data, we plan to investigate the 
quantitative relationships between gene expression and the two forms of DNA methylation at 
promoters, enhancers, and gene bodies (261). More specifically, even though the base-pair 
resolution is lower for hMeDIP-seq than WGBS, we can compute the average methylation and 
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hydroxymethylation by 150bp to 200bp windows. In addition, we can explore the correlation 
between DMRs and hyper-5hmC regions, and further study their regulatory role of gene 
expression by integrating them with RNA-seq data. 
 As part of the future directions, we are interested in the role of 5hmC in other cancer 
types, particularly the cancers that are associated with HPV infection, such as cervical cancer, 
where more than 95% of the cases are HPV(+). One preliminary study characterized the 5mC 
and 5hmC profiles in cervical cancer using MeDIP-seq and hMeDIP-seq, where the group 
identified downregulation of 5hmC in cancer compared with control samples (262). Due to the 
lack of control samples in our HNSCC study, we cannot compare our DMRs and DhMRs with 
those discovered in the cervical cancer study. However, we can use a similar approach to study 
5mC and 5hmC together in HNSCC, and explore the trend of 5hmC distribution across the 
genome, especially in HPV(+) tumors. Just as we discovered the HPV(+) subtypes within 
HNSCC, a similar approach can be used on the gene expression and epigenetic profiles of 
cervical cancers to further define biologically meaningful subtypes. By conducting additional 
sequencing to capture 5hmC profiles in HPV(-) cervical cancers and comparing HPV(+) with 
HPV(-) tumors, we will be able to better understand the epigenetic effects of HPV infection in 
cervical cancers. 
 
5.3 Improved characterization of immune response in IRX-2 immunotherapy 
 Based on the caveats discussed in Chapter 3, we propose a few ways to improve the IRX-
2 immunotherapy study. As an immunomodulatory drug, the immunotherapy with IRX-2 
regimen is expected to boost the host immune response, converting the tumor status from “cold” 
to “hot” by activating key elements of the tumor microenvironment. We did observe 
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upregulation of more than 50 immune-related genes after the treatment with IRX-2, but these 
changes are not specific to the cytokine components of the IRX-2 regimen. Although we did not 
identify any significant differential methylation between biopsy and resection samples in either 
regimen, we found a high concordance in estimated CD8+ T cells between cell type 
deconvolution and manual cell type counts (TMA). One of the main limitations of this study lies 
with the fact that NanoString technology only measures the expression of 730 immune response 
genes, but IRX-2 is involved in many biological processes not limited to immune response. If we 
can conduct RNA-seq on the same cohort, we will get a more comprehensive gene expression 
profile both before and after treatment, and better understand the functions of IRX-2 by 
conducting downstream pathway and network analyses. Second, we plan to perform manual cell 
type counts on more samples. The immune responder criterion used in our study is defined as 
patients having an increase of more than 10 CD8+ cells / mm2, but this information is only 
available in 26 out of a total of 96 patients which greatly restricted the interpretation on the 
correlation between immune response genes and immune response in patients. Last, we also plan 
to expand the cohort to better study the DNA methylation shifts during IRX-2 treatment. So far, 
we only measured the methylation level in 24 patients using the EPIC BeadChip, and very few 
immune responder patients were included in the methylation analysis. The cell type 
deconvolution analysis on more patients would provide a useful confirmation of the impact of 
IRX-2 immunotherapy in changing different cell type proportions, especially in immune cells.  
 
5.4 Effects of epigenetic modifications on other types of environmental exposures 
 The different types of environmental exposures TaRGET II consortium covers are 
arsenic, lead (Pb), bisphenol A (BPA), tributyltin (TBT), DEHP, the dioxin tetrachlorodibenzo-
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p-dioxin (TCDD), and air pollution in the form of particulate matter <2.5μ (PM2.5) (204). Aiming 
to explore the conservation of perturbations in epigenomic marks across target tissues/cells 
(adversely affected by environmental exposures) and surrogate tissues/cells (easily accessible 
and reflect the environmental exposures), the consortium has listed potential target tissues and 
surrogate tissues for each exposure separately in mouse models. In Chapter 4, we reported the 
effects of perinatal DEHP exposure on DNA methylation shift and gene expression profiles, and 
discovered that as a surrogate tissue, epigenetic changes in blood did not reflect those in liver, 
therefore not being a good surrogate tissue. In another study on epigenetics effects of perinatal 
lead exposure, a similar inconsistency was found between DNA methylation profile of liver and 
blood (230), indicating blood does not serve as a good surrogate tissue for liver in lead exposures 
either. 
 Now that we have a better understanding of the correlation between target and surrogate 
tissues based on DNA methylation, as the next step, we plan to explore the effects of other 
epigenetic modifications in DEHP, lead and other types of environmental exposures. For 
instance, previous studies linked 5hmC with different types of environmental exposures, such as 
particulate air pollution, Bisphenol A, hydroquinone and pentachlorophenol metabolites (263), 
but rarely were these studies conducted on a genome-wide scale. Based on the established 
association between DEHP exposures across three generations and significant changes in Tet1 
and Tet2 expression in liver (118), we hypothesize that pre- and peri-natal DEHP exposure will 
shift the corresponding 5hmC profiles, especially in the target tissues of DEHP (brain, kidney 
and liver). Lead exposure can induce oxidative stress, and was previously linked with increased 
5hmC and decreased 5hmC (264,265). The consortium has collected brain (cortex) tissues of 
mice of both sexes that are either exposed to lead or unexposed, and plan to quantify the 
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genome-wide 5hmC using hMeDIP-seq, so that we can further understand the sex-specific 
reprogramming of 5hmC with perinatal lead exposure. The epigenetic impact of BPA has been 
observed in many forms, including DNA methylation, hydroxymethylation, histone marks, and 
non-coding RNAs (238,266), but there is still a need to capture these epigenetic marks more 
systematically and at a genome-wide scale. 
 One of the biggest challenges in studying epigenetic effects of environmental exposures 
lies with the large variability within and between exposure groups, age groups, tissue types, and 
populations (259). Even though the use of animal models provides consistent and stable exposure 
regimes, gaps remain in the representation of different human populations and phenotypes that 
need to be addressed (266). Since health outcomes associated with both environmental exposures 
and epigenetic alterations can take years or generations to occur after the initial exposure, it is 
essential to have enough follow-up time and take measurements at multiple end points to study 
the long-term effects (267). The TaRGET II consortium not only enables improved 
understanding of the use of surrogate tissues in different exposure types, but also links 
epigenetics with transcriptomics at different time points, which casts light on understanding the 
regulatory mechanisms and aging effects of different epigenetic marks. 
 
5.5 Closing statements 
 In this dissertation we captured and examined epigenetic signatures in head and neck 
cancer and DEHP exposure using high-throughput sequencing methods. Environment itself 
greatly impacts intergenerational and transgenerational epigenetic inheritance (268), and both 
cancers and exposures are examples of the environment. The interplay between epigenetics and 
DNA sequences is extremely crucial in the development of life sciences, affecting different 
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processes of the “Central Dogma”. The use of more advanced bioinformatics tools and pipelines 
greatly improve our understanding of the genetic and epigenetic mechanisms. In addition to 
investigating the genetics and epigenetics with new assays in new diseases, we should also focus 
on the interpretation and integration of existing data to further explore diseases from a more 
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